Prospective Evaluation of the Radiographic Efficacy of Enbrel

A PROSPECTIVE EVALUATION OF THE RADIOGRAPHIC EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIATIC ARTHRITIS.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01623752

Acronym

PRERA

Enrollment

1821

Registered

2012-06-20

Start date

2012-02-29

Completion date

2018-03-31

Last updated

2019-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis Arthritis, Rheumatoid Arthritis

Brief summary

It is known from the COMET-trial that patients who start Enbrel treatment early have a great chance of reaching clinical remission and radiographic nonprogression. It is still unclear, however, how many patients with early arthritis achieve remission and radiographic nonprogression under the conditions of routine rheumatologic care and the local recommendations of Enbrel treatment (pre-treatment of at least 2 DMARDs, one of them MTX). Therefore, no robust x-ray data are available to show/demonstrate * the average extent of x-ray damage in routine patients on Enbrel outside clinical studies. * if the outstanding effect on structural damage of Enbrel can be reproduced in routine practice. * that the 'Silent Progressor' is an issue relevant not only in clinical trials, but also for day-to-day decision making. * the optimal onset of Enbrel treatment in the course of the disease to prevent radiographic damage

Detailed description

Non-interventional study: subjects to be selected according to the usual clinical practice of their physician

Interventions

DRUGEtanercept

The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subject eligibility should be reviewed and documented by an appropriately qualified member of the investigator's study team before subjects are included in the study. * Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study is a requirement for inclusion into this study. Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study: * Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. * Definitive diagnosis of RA or PsA. * Eligible for Etanercept treatment according to Summary of Product Characteristics (SmPC). * Inclusion of subjects pretreated with other biologics other than Etanercept is possible * One plain radiograph of hands and feet (Anteroposterior) within 3 month prior to initiation of treatment with Etanercept and one planned consecutive radiograph of hand and feet taken over 12 to 18 months according to German recommendations for patients treated with biologics.

Exclusion criteria

* Receipt of any investigational drug within 3 months of study inclusion. *

Design outcomes

Primary

Measure	Time frame	Description
Change From Baseline in Van Der Heijde Total Modified Total Sharp Score or Adapted mTSS at End of Phase 2 (Week 156): CAS	Baseline, Week 156	To assess radiological damage, mTSS score was used in participants with rheumatoid arthritis and mTSS adapted score was used in participants with psoriatic arthritis. Radiographs of the hands and feet were assessed by central raters. Total mTSS score range was 0 (no radiological damage) to 448 (extreme radiological damage); and total mTSS adapted score range was 0 (no radiological damage) to 528 (extreme radiological damage), where higher mTSS and mTSS adapted scores indicate a worse health status in participants with rheumatoid arthritis and participants with psoriatic arthritis, respectively.
Change From Baseline in Van Der Heijde Total Modified Total Sharp Score or Adapted mTSS at the End of Phase 2 (Week 156): EAS	Baseline, Week 156	To assess radiological damage, mTSS score was used in participants with rheumatoid arthritis and mTSS adapted score was used in participants with psoriatic arthritis. Radiographs of the hands and feet were assessed by central raters. Total mTSS score range was 0 (no radiological damage) to 448 (extreme radiological damage); and total mTSS adapted score range was 0 (no radiological damage) to 528 (extreme radiological damage), where higher mTSS and mTSS adapted scores indicate a worse health status in participants with rheumatoid arthritis and participants with psoriatic arthritis, respectively.
Change From Baseline in Van Der Heijde Total Modified Total Sharp Score or Adapted mTSS at End of Phase 1 (Week 78): Completer Analysis Set (CAS)	Baseline, Week 78	To assess radiological damage, mTSS score was used in participants with rheumatoid arthritis and mTSS adapted score was used in participants with psoriatic arthritis. Radiographs of the hands and feet were assessed by central raters. Total mTSS score range was 0 (no radiological damage) to 448 (extreme radiological damage); and total mTSS adapted score range was 0 (no radiological damage) to 528 (extreme radiological damage), where higher mTSS and mTSS adapted scores indicate a worse health status in participants with rheumatoid arthritis and participants with psoriatic arthritis, respectively.
Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at the End of Phase 2 (Week 156): CAS	Pre-treatment, Week 156	The normalized change in total scores (mTSS or mTSS adapted) were computed as normalized per year (normalized progression). The change of normalized progression was classified as: increase (\>0.5), no change (-0.5 to 0.5) and decrease (\<-0.5). Participants with no change or a decrease were considered to be in radiographic remission.
Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at End of Phase 2 (Week 156): EAS	Pre-treatment, Week 156	The normalized change in total scores (mTSS or mTSS adapted) were computed as normalized per year (normalized progression). The change of normalized progression was classified as: increase (\>0.5), no change (-0.5 to 0.5) and decrease (\<-0.5). Participants with no change or a decrease were considered to be in radiographic remission.
Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at End of Phase 1 (Week 78): CAS	Pre-treatment, Week 78	The normalized change in total scores (mTSS or mTSS adapted) were computed as normalized per year (normalized progression). The change of normalized progression was classified as: increase (\>0.5), no change (-0.5 to 0.5) and decrease (\<-0.5). Participants with no change or a decrease were considered to be in radiographic remission.
Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at End of Phase 1 (Week 78): EAS	Pre-treatment, Week 78	The normalized change in total scores (mTSS or mTSS adapted) were computed as normalized per year (normalized progression). The change of normalized progression was classified as: increase (greater than \[\>\] 0.5), no change (-0.5 to 0.5) and decrease (less than \[\<\] -0.5). Participants with no change or a decrease were considered to be in radiographic remission.
Change From Baseline in Van Der Heijde Total Modified Total Sharp Score (mTSS) or Adapted mTSS at End of Phase 1 (Week 78): Efficacy Analysis Set (EAS)	Baseline, Week 78	To assess radiological damage mTSS score was used in participants with rheumatoid arthritis and mTSS adapted score was used in participants with psoriatic arthritis. Radiographs of the hands and feet were assessed by central raters. Total mTSS score range was 0 (no radiological damage) to 448 (extreme radiological damage); and total mTSS adapted score range was 0 (no radiological damage) to 528 (extreme radiological damage), where higher mTSS and mTSS adapted scores indicate a worse health status in participants with rheumatoid arthritis and participants with psoriatic arthritis, respectively.

Secondary

Measure	Time frame	Description
Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156	FFbH is a self-administered patient questionnaire composed by 18 questions on functional ability in activities of daily living. Each question was answered by the participant as Yes, I can perform the activity without difficulty (score assigned =2), Yes, but with difficulties (score assigned =1) and No or only with external help (score assigned =0). Final FFbH score (%) was then computed according to formula: (Sum of scores\100) divided by (2\number of valid answers), ranging between 0 (no functional capacity) to 100 (full functional capacity); higher scores indicate better daily activities. FFbH functional remission was defined as FFbH functional capacity of \>= 83%.
Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156	DAS28 was calculated from swollen joint count and tender joint count using 28 joint count, C-reactive protein (CRP) in milligram per liter (mg/L) and participant global assessment (PtGA) of disease activity measured on a 100 mm visual analog scale (VAS) ranging from 0 (good condition) to 100 (worst condition), where higher scores indicate worse health condition). DAS28 total score range: 0 (no disease activity) to 9.4 (maximum disease activity), higher score indicates more disease activity. DAS-28 score of 2.6 to 3.2= low, 3.2 to 5.1= moderate and \>5.1= high disease activity. DAS-28 score of \<2.6= disease remission. DAS28-4(CRP) = (0.56\sqrt\[TJC28\] + 0.28\sqrt\[SJC28\] + 0.36\ln\[CRP+1\]) + 0.014\GH + 0.96) and DAS28-4(ESR) = (0.56\sqrt\[TJC28\] + 0.28\sqrt\[SJC28\] + 0.70\ln\[ESR\] + 0.014\GH), where sqrt = square root, ln = natural logarithm.
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156	CDAI was calculated from tender and swollen joints using 28 joint count, participant global assessment (PtGA) and physician global assessment (PhyGA). PtGA and PhyGA both were assessed on 0-100 mm VAS scale, where higher scores indicated greater affection due to disease activity. CDAI total score ranged from 0 to 76, where higher scores indicated higher disease activity. CDAI score of \<=10 indicates low disease activity and a score of \<= 2.8 indicates remission.
Change From Baseline in Simple Disease Activity Index (SDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156	SDAI was calculated from tender and swollen joints using 28 joint count, participant global assessment (PtGA), physician global assessment and (PhyGA) and CRP (in mg/L). PtGA and PhyGA both were assessed on 0-100 mm VAS scale, where higher scores indicated greater affection due to disease activity. SDAI total score ranged from 0 to 86, where higher scores indicated higher disease activity. SDAI score of \<=11 indicates low disease activity and a score of \<=3.3 indicates remission.
Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156	CDAI was calculated from tender and swollen joints using 28 joint count, PtGA and PhyGA. CDAI total score ranged from 0 to 76, where higher scores indicated higher disease activity. CDAI score of \<=10 indicates low disease activity and a score of \<= 2.8 indicates remission. SDAI was calculated from tender and swollen joints using 28 joint count, PtGA, PhyGA and CRP (in mg/L). SDAI total score ranged from 0 to 86, where higher scores indicated higher disease activity. SDAI score of \<=11 indicates low disease activity and a score of \<=3.3 indicates remission. PtGA and PhyGA both were assessed on 0-100 mm VAS scale, where higher scores indicated greater affection due to disease activity.
Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156	VAS: participants placed a mark indicating the intensity of their pain on a scale of 0 (no pain) to 100 mm (worst possible pain). Higher scores indicate greater level of pain.
Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156	PhyGA: physician marked intensity of participants' pain on a visual analogue scale of 0 (no disease activity) to 100 mm (worst possible condition). Higher scores indicate greater level of disease activity.
Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156	PtGA: participant assessed their disease activity using a 100 mm visual analog scale ranging from 0 = very good to 100 = worst. Higher scores indicate worse health status.
Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156	EQ-5D: participant rated questionnaire to assess generic health status in two parts: single utility score and visual analog scale. For utility score, participants rated their current health state on 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression with each dimension having three levels of function: 1 indicates no problem; 2 indicates some problem; 3 indicates extreme problem.
Duration of Morning Stiffness in Participants With Temporary Rigidity	Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156	Rigidity was temporary when 'Yes' was given for the question if daily activities could be done without stiffness; rigidity was permanent when 'No' was given for the question if daily activities could be done without stiffness.
Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156	Participants with psoriatic arthritis were distributed in following different classes depending upon percentage (%) of BSA affected: 1) less than (\<) 3 %, 2) 3-10%, 3) 11-20% and 4) \>20%. Psoriatic arthritis affecting \<3% BSA was considered as mild, 3 to 10 % as moderate and \>10 percent as severe.
Change From Baseline in Nail Involvement at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156	In this outcome measure change in number of nails affected by psoriatic arthritis at specified week compared to baseline is reported. Nails included both finger nails and toe nails.
Change From Baseline in Inflamed Dactylitic Digits at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156	In this outcome measure change in number of inflamed dactylitic digits at specified week compared to baseline is reported. Dactylitis is inflammation of dactylitic digits (fingers and toes).
Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	Baseline, Week 78, 156	In this outcome measure number of participants with use of glucocorticoids and DMARDs at baseline and specified weeks are reported. If participants used glucocorticoids and DMARDs, it was denoted by Yes and if they did not use, it was denoted by No. Data have been reported separately for glucocorticoids and DMARDs at specified weeks respectively, in 4 categories as: 1) Baseline: No and Specified Week: No, 2) Baseline: Yes and Specified Week: No, 3) Baseline: No and Specified Week: Yes, 4) Baseline: Yes and Specified Week: Yes.
Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Continuation of Treatment With Etanercept	Baseline up to Week 156	In this outcome number of participants who participated or not participated in RUDI and PIT and impact of their participation in continuation or termination of treatment with Etanercept is reported. For participants whom data was not recorded is reported under category No Data.
Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline up to Week 156	In this outcome number of participants who participated or not participated in RUDI and PIT and impact of their participation in quality of life parameters using EQ-5D health questionnaire is reported. For participants whom data was not recorded is reported under category No Data. EQ-5D: participant rated questionnaire to assess generic health status in two parts: single utility score and visual analog scale. For utility score, participants rated their current health state on 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression with each dimension having three levels of function: 1 indicates no problem; 2 indicates some problem; 3 indicates extreme problem.
Percentage of Participants With Rheumatoid Arthritis, With Remission Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156	CDAI was calculated from tender and swollen joints using 28 joint count, PtGA and PhyGA. CDAI total score ranged from 0 to 76, where higher scores indicated higher disease activity. CDAI score of \<=10 indicates low disease activity and a score of \<= 2.8 indicates remission. SDAI was calculated from tender and swollen joints using 28 joint count, PtGA, PhyGA and CRP (in mg/L). SDAI total score ranged from 0 to 86, where higher scores indicated higher disease activity. SDAI score of \<=11 indicates low disease activity and a score of \<=3.3 indicates remission. PtGA and PhyGA both were assessed on 0-100 mm VAS scale, where higher scores indicated greater affection due to disease activity.
Linear Relationship Between Normalized Radiographic Progression and Disease Duration	Baseline up to Week 78	Linear relationship between radiographic progression and disease duration was evaluated using a linear regression model. Dependent variable was normalized progression under treatment with Etanercept and independent variable was disease duration.
Effect on Normalized Radiographic Progression With Respect to Baseline Positivity of Anti-citrullinated Protein Antibody (ACPA) - Rheumatoid Factor (RF)	Baseline up to Week 78	Effect on normalized radiographic progression with respect to ACPA-RF was evaluated using an analysis of variance (ANOVA) model. Dependent variable was normalized progression under treatment with Etanercept and independent variable was groups of positive testing of ACPA and RF at baseline.
Effect on Normalized Radiographic Progression With Respect to Baseline Usage of Concomitant Medication	Baseline up to Week 78	Effect on normalized radiographic progression with respect to use of concomitant medication at baseline was evaluated using an ANOVA model. Dependent variable was normalized progression under treatment with Etanercept and independent variable was groups of concomitant medication as found among the medication given concomitantly during study that is recorded at baseline.
Effect on Normalized Radiographic Progression With Respect to Previous Treatment With Biologics	Baseline up to Week 78	Effect on normalized radiographic progression of previous treatment with biologics was evaluated using an ANOVA model. Dependent variable was normalized progression under treatment with Etanercept and independent variable was previous treatment with biologics.
Effect on Normalized Radiographic Progression With Respect to Baseline Disease Activity Score-28 (DAS-28)	Baseline up to Week 78	Effect on radiographic progression with respect to baseline DAS-28 was evaluated using ANOVA model. Dependent variable was normalized progression under treatment with Etanercept and independent variable was baseline DAS-28. Baseline DAS-28 is less than or equal to (\<=) 5.1 or \>5.1. DAS28: score range from 0 (none) to 9.4 (extreme disease activity); low =2.6 to 3.2, moderate =3.2 to 5.1, and high disease activity \>5.1. DAS28 score of \<2.6 indicates disease remission.
Change From Baseline in Total Erosion Score at End of Phase 1 (Week 78) and Phase 2 (Week 156)	Baseline, Week 78, 156	Total erosion score as per van der Hejde method consisted of 2 dimensions: a) hands (32 erosion locations, each location graded from 0 \[no erosion\] to 5 \[maximum severity\], sum of grading of each location resulted in score of 0 to 160); and b) feet (12 erosion locations, each location graded from 0 \[no erosion\] to 10 \[maximum severity\], sum of grading of each location resulted in score of 0 to 120). Sum of erosion scores of hand (0 to 160) and feet (0 to 120) gave a total erosion score as 0 to 280, where 0 was no erosion at all and 280 was worst possible condition, higher scores indicated severe joint destruction.
Change From Baseline in Total Joint Space Narrow Score at End of Phase 1 (Week 78) and Phase 2 (Week 156)	Baseline, Week 78, 156	Total joint space narrow score as per van der Hejde method consisted of 2 dimensions: a) hands (30 joint space locations, each location graded from 0 \[normal joint space\] to 4 \[bony ankylosis\], sum of grading of each location resulted in score of 0 to 120); and b) feet (12 erosion locations, each location graded from 0 \[no erosion\] to 4 \[bony ankylosis\], sum of grading of each location resulted in score of 0 to 48). Sum of joint space narrow scores of hand (0 to 120) and feet (0 to 48) gave a total joint space narrow score as 0 to 168, where 0 was normal joint space and 168 was maximum narrowing in joints, higher scores indicated severe joint destruction.

Other

Measure	Time frame	Description
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)	Baseline up to Week 156	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events.
Number of Participants Who Used Concomitant Medication	Baseline up to Week 156	Number of participants who used medication other than Etanercept for relief of pain. It was determined by the treating physician.
Number of Participants With Pregnancy, Puerperium and Perinatal Conditions	Baseline up to Week 156	In this outcome measure total number of participants with pregnancy, puerperium and perinatal conditions are reported. Pregnancy, puerperium and perinatal conditions included pregnancy, abortion, abortion spontaneous or premature baby.
Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78, 156	Physicians and participants rated the tolerability of Etanercept treatment by means of a 4-point scale as: 1) very good, 2) good, 3) moderate and 4) insufficient.
Number of Participants With Treatment-Emergent Treatment Related Adverse Events	Baseline up to Week 156	Treatment-related AE was any untoward medical occurrence in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events. Relatedness to study treatment was assessed by the investigator.
Number of Participants With Discontinuation of Etanercept Treatment	Week 78, 156	Number of participants those who discontinued Etanercept treatment at Week 78 and 156 are reported in this outcome measure.
Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity	Baseline up to Week 156	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events. AEs were classified according to the severity in 3 categories a)mild: AEs not interfered with participant's usual function b)moderate: AEs interfered to some extent with participant's usual function c)severe: AEs interfered significantly with participant's usual function. Participants may be counted in more than 1 category.

Participant flow

Recruitment details

Participants those who were recruited despite of an unknown or unclear disease diagnosis, were only included in safety analysis for the study, not for efficacy evaluation.

Participants by arm

Arm	Count
Participants With Rheumatoid Arthritis Participants with rheumatoid arthritis, who were on Etanercept routine treatment (as per the requirements of the labelling of Enbrel in Germany; dosage and duration of therapy was determined by the physician to meet the participants' individual needs for treatment), were observed for safety and radiological efficacy up to Week 156. During Phase 1 participants were followed up after every 13 weeks up to Week 78 and during Phase 2 participants were followed up after every 16 weeks from Week 78 till Week 156.	1,378
Participants With Psoriatic Arthritis Participants with psoriatic arthritis, who were on Etanercept routine treatment (as per the requirements of the labelling of Enbrel in Germany; dosage and duration of therapy was determined by the physician to meet the participants' individual needs for treatment), were observed for safety and radiological efficacy up to Week 156. During Phase 1 participants were followed up after every 13 weeks up to Week 78 and during Phase 2 participants were followed up after every 16 weeks from Week 78 till Week 156.	440
Participants With Unclear Diagnosis Participants with unclear diagnosis, who were on Etanercept routine treatment (as per the requirements of the labelling of Enbrel in Germany; dosage and duration of therapy was determined by the physician to meet the participants' individual needs for treatment), were observed for safety and radiological efficacy up to Week 156. During Phase 1 participants were followed up after every 13 weeks up to Week 78 and during Phase 2 participants were followed up after every 16 weeks from Week 78 till Week 156.	3
Total	1,821

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002
Phase 1 (78 Weeks)	Adverse Event	122	39	0
Phase 1 (78 Weeks)	Lack of Efficacy	227	82	0
Phase 1 (78 Weeks)	No Data	249	66	2
Phase 1 (78 Weeks)	Other	33	20	0
Phase 2 (78 Weeks)	Adverse Event	4	4	0
Phase 2 (78 Weeks)	Lack of Efficacy	14	2	0
Phase 2 (78 Weeks)	No Data	43	11	0
Phase 2 (78 Weeks)	Other	5	1	0

Baseline characteristics

Characteristic	Participants With Rheumatoid Arthritis	Total	Participants With Unclear Diagnosis	Participants With Psoriatic Arthritis
Age, Customized 18 to 64 years	976 Participants	1365 Participants	2 Participants	387 Participants
Age, Customized 65 years or more	395 Participants	444 Participants	0 Participants	49 Participants
Age, Customized Less than 18 years	1 Participants	1 Participants	0 Participants	0 Participants
Age, Customized No data	6 Participants	11 Participants	1 Participants	4 Participants
Race and Ethnicity Not Collected	—	0 Participants	—	—
Sex/Gender, Customized Female	1062 Participants	1323 Participants	2 Participants	259 Participants
Sex/Gender, Customized Male	316 Participants	497 Participants	0 Participants	181 Participants
Sex/Gender, Customized No Data	0 Participants	1 Participants	1 Participants	0 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk
deaths Total, all-cause mortality	6 / 1,378	0 / 440	0 / 3
other Total, other adverse events	579 / 1,378	167 / 440	1 / 3
serious Total, serious adverse events	159 / 1,378	47 / 440	0 / 3

Outcome results

Primary

Change From Baseline in Van Der Heijde Total Modified Total Sharp Score (mTSS) or Adapted mTSS at End of Phase 1 (Week 78): Efficacy Analysis Set (EAS)

To assess radiological damage mTSS score was used in participants with rheumatoid arthritis and mTSS adapted score was used in participants with psoriatic arthritis. Radiographs of the hands and feet were assessed by central raters. Total mTSS score range was 0 (no radiological damage) to 448 (extreme radiological damage); and total mTSS adapted score range was 0 (no radiological damage) to 528 (extreme radiological damage), where higher mTSS and mTSS adapted scores indicate a worse health status in participants with rheumatoid arthritis and participants with psoriatic arthritis, respectively.

Time frame: Baseline, Week 78

Population: Efficacy analysis set for Phase 1= all participants who had received at least 1 dose of Etanercept and had baseline X-ray (Rx1) and end of phase 1 X-ray (Rx2). Here, Overall Number of Participants Analyzed =number of participants evaluable for this outcome measure; Number Analyzed=number of participants evaluable for the specified time points.

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants With Rheumatoid Arthritis	Change From Baseline in Van Der Heijde Total Modified Total Sharp Score (mTSS) or Adapted mTSS at End of Phase 1 (Week 78): Efficacy Analysis Set (EAS)	Baseline	25.1 Units on a scale	Standard Deviation 42.4
Participants With Rheumatoid Arthritis	Change From Baseline in Van Der Heijde Total Modified Total Sharp Score (mTSS) or Adapted mTSS at End of Phase 1 (Week 78): Efficacy Analysis Set (EAS)	Change at Week 78	0.6 Units on a scale	Standard Deviation 7.2
Participants With Psoriatic Arthritis	Change From Baseline in Van Der Heijde Total Modified Total Sharp Score (mTSS) or Adapted mTSS at End of Phase 1 (Week 78): Efficacy Analysis Set (EAS)	Baseline	14.7 Units on a scale	Standard Deviation 25.7
Participants With Psoriatic Arthritis	Change From Baseline in Van Der Heijde Total Modified Total Sharp Score (mTSS) or Adapted mTSS at End of Phase 1 (Week 78): Efficacy Analysis Set (EAS)	Change at Week 78	-0.4 Units on a scale	Standard Deviation 5.9

Primary

Change From Baseline in Van Der Heijde Total Modified Total Sharp Score or Adapted mTSS at End of Phase 1 (Week 78): Completer Analysis Set (CAS)

To assess radiological damage, mTSS score was used in participants with rheumatoid arthritis and mTSS adapted score was used in participants with psoriatic arthritis. Radiographs of the hands and feet were assessed by central raters. Total mTSS score range was 0 (no radiological damage) to 448 (extreme radiological damage); and total mTSS adapted score range was 0 (no radiological damage) to 528 (extreme radiological damage), where higher mTSS and mTSS adapted scores indicate a worse health status in participants with rheumatoid arthritis and participants with psoriatic arthritis, respectively.

Time frame: Baseline, Week 78

Population: Completer analysis set for Phase 1: all participants who had received at least 1 dose of Etanercept and had clinical data for Rx1 and Rx2 and provided data for end of Phase 1 of study. Overall Number of Participants Analyzed = participants evaluable for this outcome measure. Number Analyzed= participants evaluable for the specified time points.

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants With Rheumatoid Arthritis	Change From Baseline in Van Der Heijde Total Modified Total Sharp Score or Adapted mTSS at End of Phase 1 (Week 78): Completer Analysis Set (CAS)	Baseline	25.3 Units on a scale	Standard Deviation 42.5
Participants With Rheumatoid Arthritis	Change From Baseline in Van Der Heijde Total Modified Total Sharp Score or Adapted mTSS at End of Phase 1 (Week 78): Completer Analysis Set (CAS)	Change at Week 78	0.6 Units on a scale	Standard Deviation 7.2
Participants With Psoriatic Arthritis	Change From Baseline in Van Der Heijde Total Modified Total Sharp Score or Adapted mTSS at End of Phase 1 (Week 78): Completer Analysis Set (CAS)	Baseline	14.7 Units on a scale	Standard Deviation 25.8
Participants With Psoriatic Arthritis	Change From Baseline in Van Der Heijde Total Modified Total Sharp Score or Adapted mTSS at End of Phase 1 (Week 78): Completer Analysis Set (CAS)	Change at Week 78	-0.5 Units on a scale	Standard Deviation 5.8

Primary

Change From Baseline in Van Der Heijde Total Modified Total Sharp Score or Adapted mTSS at End of Phase 2 (Week 156): CAS

Time frame: Baseline, Week 156

Population: Completer analysis set for Phase 2 included all participants who had received at least 1 dose of Etanercept, and had clinical data for the obligatory X-ray (Rx1) and Rx3, and completed Phase 2 of the study. Here, Overall Number of Participants Analyzed signifies number of participants evaluable for this outcome measure.

Arm	Measure	Value (MEAN)	Dispersion
Participants With Rheumatoid Arthritis	Change From Baseline in Van Der Heijde Total Modified Total Sharp Score or Adapted mTSS at End of Phase 2 (Week 156): CAS	1.4 Units on a scale	Standard Deviation 9.9
Participants With Psoriatic Arthritis	Change From Baseline in Van Der Heijde Total Modified Total Sharp Score or Adapted mTSS at End of Phase 2 (Week 156): CAS	0.7 Units on a scale	Standard Deviation 8.2

Primary

Change From Baseline in Van Der Heijde Total Modified Total Sharp Score or Adapted mTSS at the End of Phase 2 (Week 156): EAS

Time frame: Baseline, Week 156

Population: Efficacy analysis set for Phase 2 included all participants who had received at least 1 dose of Etanercept and had Rx1 and end of Phase 2 X-ray (Rx3). Here, Overall Number of Participants Analyzed signifies number of participants evaluable for this outcome measure.

Arm	Measure	Value (MEAN)	Dispersion
Participants With Rheumatoid Arthritis	Change From Baseline in Van Der Heijde Total Modified Total Sharp Score or Adapted mTSS at the End of Phase 2 (Week 156): EAS	1.4 Units on a scale	Standard Deviation 9.9
Participants With Psoriatic Arthritis	Change From Baseline in Van Der Heijde Total Modified Total Sharp Score or Adapted mTSS at the End of Phase 2 (Week 156): EAS	0.7 Units on a scale	Standard Deviation 8.2

Primary

Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at End of Phase 1 (Week 78): CAS

The normalized change in total scores (mTSS or mTSS adapted) were computed as normalized per year (normalized progression). The change of normalized progression was classified as: increase (\>0.5), no change (-0.5 to 0.5) and decrease (\<-0.5). Participants with no change or a decrease were considered to be in radiographic remission.

Time frame: Pre-treatment, Week 78

Population: CAS for phase 1 included all participants who had received at least 1 dose of Etanercept, and had Rx1 and Rx2, and provided data for end of Phase 1 of study. Here, Overall Number of Participants Analyzed=number of participants evaluable for this outcome measure and Number Analyzed=number of participants evaluable for the specified time points.

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants With Rheumatoid Arthritis	Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at End of Phase 1 (Week 78): CAS	Change at Week 78	-0.306 Scores per year	Standard Deviation 6.002
Participants With Rheumatoid Arthritis	Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at End of Phase 1 (Week 78): CAS	Pre-treatment	0.981 Scores per year	Standard Deviation 4.413
Participants With Psoriatic Arthritis	Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at End of Phase 1 (Week 78): CAS	Pre-treatment	1.080 Scores per year	Standard Deviation 5.182
Participants With Psoriatic Arthritis	Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at End of Phase 1 (Week 78): CAS	Change at Week 78	-1.033 Scores per year	Standard Deviation 8.724

Comparison: P-value was calculated using Paired t-test for the change in normalized progression.p-value: 0.251Paired t-test

Comparison: P-value was calculated using Paired t-test for the change in normalized progression.p-value: 0.218Paired t-test

Primary

Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at End of Phase 1 (Week 78): EAS

The normalized change in total scores (mTSS or mTSS adapted) were computed as normalized per year (normalized progression). The change of normalized progression was classified as: increase (greater than \[\>\] 0.5), no change (-0.5 to 0.5) and decrease (less than \[\<\] -0.5). Participants with no change or a decrease were considered to be in radiographic remission.

Time frame: Pre-treatment, Week 78

Population: Efficacy analysis set for Phase 1 included all participants who had received at least 1 dose of Etanercept and had Rx1 and Rx2. Here, Overall Number of Participants Analyzed = number of participants evaluable for this outcome measure and Number Analyzed = number of participants evaluable for the specified time points.

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants With Rheumatoid Arthritis	Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at End of Phase 1 (Week 78): EAS	Change at Week 78	-0.267 Scores per year	Standard Deviation 5.989
Participants With Rheumatoid Arthritis	Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at End of Phase 1 (Week 78): EAS	Pre-treatment	0.959 Scores per year	Standard Deviation 4.396
Participants With Psoriatic Arthritis	Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at End of Phase 1 (Week 78): EAS	Pre-treatment	1.056 Scores per year	Standard Deviation 5.127
Participants With Psoriatic Arthritis	Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at End of Phase 1 (Week 78): EAS	Change at Week 78	-0.995 Scores per year	Standard Deviation 8.628

Comparison: P-value was calculated using Paired t-test for the change in normalized progression.p-value: 0.278Paired t-test

Comparison: P-value was calculated using Paired t-test for the change in normalized progression.p-value: 0.222Paired t-test

Primary

Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at End of Phase 2 (Week 156): EAS

Time frame: Pre-treatment, Week 156

Population: Efficacy analysis set for Phase 2 included all participants who had received at least 1 dose of Etanercept and had Rx1 and Rx3. Here, Overall Number of Participants Analyzed signifies number of participants evaluable for this outcome measure.

Arm	Measure	Value (MEAN)	Dispersion
Participants With Rheumatoid Arthritis	Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at End of Phase 2 (Week 156): EAS	-0.473 Scores per year	Standard Deviation 5.94
Participants With Psoriatic Arthritis	Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at End of Phase 2 (Week 156): EAS	-0.348 Scores per year	Standard Deviation 3.985

Primary

Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at the End of Phase 2 (Week 156): CAS

Time frame: Pre-treatment, Week 156

Population: CAS for phase 2 included all participants who had received at least 1 dose of Etanercept, and had Rx1 and Rx2, and completed phase 2 of the study. Here, Overall Number of Participants Analyzed signifies number of participants evaluable for this outcome measure.

Arm	Measure	Value (MEAN)	Dispersion
Participants With Rheumatoid Arthritis	Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at the End of Phase 2 (Week 156): CAS	-0.473 Scores per year	Standard Deviation 5.94
Participants With Psoriatic Arthritis	Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at the End of Phase 2 (Week 156): CAS	-0.348 Scores per year	Standard Deviation 3.985

Secondary

Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis

CDAI was calculated from tender and swollen joints using 28 joint count, participant global assessment (PtGA) and physician global assessment (PhyGA). PtGA and PhyGA both were assessed on 0-100 mm VAS scale, where higher scores indicated greater affection due to disease activity. CDAI total score ranged from 0 to 76, where higher scores indicated higher disease activity. CDAI score of \<=10 indicates low disease activity and a score of \<= 2.8 indicates remission.

Time frame: Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156

Population: Full analysis set: all participants who received at least 1 dose of Etanercept and had at least 1 effectiveness measurement after start of treatment. Number Analyzed = number of participants evaluable for the specified time points. Data for this outcome measure was to be collected and evaluated only for participants with rheumatoid arthritis.

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants With Rheumatoid Arthritis	Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Change at Week 104	-17.53 Units on a scale	Standard Deviation 11.99
Participants With Rheumatoid Arthritis	Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Baseline	25.64 Units on a scale	Standard Deviation 12.14
Participants With Rheumatoid Arthritis	Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Change at Week 13	-11.51 Units on a scale	Standard Deviation 12.13
Participants With Rheumatoid Arthritis	Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Change at Week 26	-13.49 Units on a scale	Standard Deviation 12.53
Participants With Rheumatoid Arthritis	Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Change at Week 39	-13.98 Units on a scale	Standard Deviation 12.78
Participants With Rheumatoid Arthritis	Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Change at Week 52	-14.32 Units on a scale	Standard Deviation 12.29
Participants With Rheumatoid Arthritis	Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Change at Week 65	-15.28 Units on a scale	Standard Deviation 12.66
Participants With Rheumatoid Arthritis	Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Change at Week 78	-15.54 Units on a scale	Standard Deviation 12.28
Participants With Rheumatoid Arthritis	Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Change at Week 130	-17.37 Units on a scale	Standard Deviation 12.18
Participants With Rheumatoid Arthritis	Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Change at Week 156	-18.38 Units on a scale	Standard Deviation 11.99

Secondary

Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156

DAS28 was calculated from swollen joint count and tender joint count using 28 joint count, C-reactive protein (CRP) in milligram per liter (mg/L) and participant global assessment (PtGA) of disease activity measured on a 100 mm visual analog scale (VAS) ranging from 0 (good condition) to 100 (worst condition), where higher scores indicate worse health condition). DAS28 total score range: 0 (no disease activity) to 9.4 (maximum disease activity), higher score indicates more disease activity. DAS-28 score of 2.6 to 3.2= low, 3.2 to 5.1= moderate and \>5.1= high disease activity. DAS-28 score of \<2.6= disease remission. DAS28-4(CRP) = (0.56\*sqrt\[TJC28\] + 0.28\*sqrt\[SJC28\] + 0.36\*ln\[CRP+1\]) + 0.014\*GH + 0.96) and DAS28-4(ESR) = (0.56\*sqrt\[TJC28\] + 0.28\*sqrt\[SJC28\] + 0.70\*ln\[ESR\] + 0.014\*GH), where sqrt = square root, ln = natural logarithm.

Time frame: Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156

Population: Full analysis set included all participants who received at least 1 dose of Etanercept and had at least 1 effectiveness measurement after start of treatment. Here, Number Analyzed signifies number of participants evaluable for the specified time points.

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants With Rheumatoid Arthritis	Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Baseline	4.63 Units on a scale	Standard Deviation 1.24
Participants With Rheumatoid Arthritis	Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 13	-1.26 Units on a scale	Standard Deviation 1.38
Participants With Rheumatoid Arthritis	Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 26	-1.52 Units on a scale	Standard Deviation 1.38
Participants With Rheumatoid Arthritis	Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 39	-1.57 Units on a scale	Standard Deviation 1.41
Participants With Rheumatoid Arthritis	Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 52	-1.64 Units on a scale	Standard Deviation 1.41
Participants With Rheumatoid Arthritis	Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 65	-1.76 Units on a scale	Standard Deviation 1.47
Participants With Rheumatoid Arthritis	Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 78	-1.73 Units on a scale	Standard Deviation 1.38
Participants With Rheumatoid Arthritis	Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 104	-1.94 Units on a scale	Standard Deviation 1.33
Participants With Rheumatoid Arthritis	Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 130	-1.96 Units on a scale	Standard Deviation 1.36
Participants With Rheumatoid Arthritis	Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 156	-2.10 Units on a scale	Standard Deviation 1.42
Participants With Psoriatic Arthritis	Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 104	-1.67 Units on a scale	Standard Deviation 1.37
Participants With Psoriatic Arthritis	Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Baseline	4.18 Units on a scale	Standard Deviation 1.11
Participants With Psoriatic Arthritis	Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 65	-1.54 Units on a scale	Standard Deviation 1.26
Participants With Psoriatic Arthritis	Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 13	-1.23 Units on a scale	Standard Deviation 1.31
Participants With Psoriatic Arthritis	Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 156	-1.54 Units on a scale	Standard Deviation 1.39
Participants With Psoriatic Arthritis	Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 26	-1.37 Units on a scale	Standard Deviation 1.28
Participants With Psoriatic Arthritis	Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 78	-1.62 Units on a scale	Standard Deviation 1.31
Participants With Psoriatic Arthritis	Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 39	-1.52 Units on a scale	Standard Deviation 1.27
Participants With Psoriatic Arthritis	Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 130	-1.66 Units on a scale	Standard Deviation 1.27
Participants With Psoriatic Arthritis	Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 52	-1.69 Units on a scale	Standard Deviation 1.2

Secondary

Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156

FFbH is a self-administered patient questionnaire composed by 18 questions on functional ability in activities of daily living. Each question was answered by the participant as Yes, I can perform the activity without difficulty (score assigned =2), Yes, but with difficulties (score assigned =1) and No or only with external help (score assigned =0). Final FFbH score (%) was then computed according to formula: (Sum of scores\*100) divided by (2\*number of valid answers), ranging between 0 (no functional capacity) to 100 (full functional capacity); higher scores indicate better daily activities. FFbH functional remission was defined as FFbH functional capacity of \>= 83%.

Time frame: Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants With Rheumatoid Arthritis	Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 13	4.38 Units on a scale	Standard Deviation 12.94
Participants With Rheumatoid Arthritis	Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 52	5.78 Units on a scale	Standard Deviation 15.27
Participants With Rheumatoid Arthritis	Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 130	6.22 Units on a scale	Standard Deviation 15.46
Participants With Rheumatoid Arthritis	Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 65	6.15 Units on a scale	Standard Deviation 15.96
Participants With Rheumatoid Arthritis	Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 26	5.63 Units on a scale	Standard Deviation 15.25
Participants With Rheumatoid Arthritis	Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 104	6.10 Units on a scale	Standard Deviation 14.98
Participants With Rheumatoid Arthritis	Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 78	6.59 Units on a scale	Standard Deviation 16.16
Participants With Rheumatoid Arthritis	Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 39	6.20 Units on a scale	Standard Deviation 15.43
Participants With Rheumatoid Arthritis	Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 156	5.54 Units on a scale	Standard Deviation 16.42
Participants With Rheumatoid Arthritis	Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Baseline	64.99 Units on a scale	Standard Deviation 22.71
Participants With Psoriatic Arthritis	Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 156	3.56 Units on a scale	Standard Deviation 15.78
Participants With Psoriatic Arthritis	Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Baseline	68.67 Units on a scale	Standard Deviation 22.09
Participants With Psoriatic Arthritis	Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 13	3.45 Units on a scale	Standard Deviation 13.44
Participants With Psoriatic Arthritis	Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 78	3.62 Units on a scale	Standard Deviation 16.37
Participants With Psoriatic Arthritis	Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 26	3.99 Units on a scale	Standard Deviation 15.11
Participants With Psoriatic Arthritis	Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 39	4.90 Units on a scale	Standard Deviation 14.46
Participants With Psoriatic Arthritis	Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 52	4.43 Units on a scale	Standard Deviation 16.47
Participants With Psoriatic Arthritis	Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 65	4.83 Units on a scale	Standard Deviation 16.52
Participants With Psoriatic Arthritis	Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 104	5.09 Units on a scale	Standard Deviation 14.54
Participants With Psoriatic Arthritis	Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 130	4.66 Units on a scale	Standard Deviation 15.03

Secondary

Change From Baseline in Inflamed Dactylitic Digits at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis

In this outcome measure change in number of inflamed dactylitic digits at specified week compared to baseline is reported. Dactylitis is inflammation of dactylitic digits (fingers and toes).

Time frame: Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156

Population: Full analysis set. Here, Number Analyzed signifies number of participants evaluable for the specified time points. Data for this outcome measure was to be collected and evaluated only for participants with psoriatic arthritis.

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants With Rheumatoid Arthritis	Change From Baseline in Inflamed Dactylitic Digits at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Baseline	0.72 Dactylitic digits	Standard Deviation 1.64
Participants With Rheumatoid Arthritis	Change From Baseline in Inflamed Dactylitic Digits at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Change at Week 13	-0.39 Dactylitic digits	Standard Deviation 1.36
Participants With Rheumatoid Arthritis	Change From Baseline in Inflamed Dactylitic Digits at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Change at Week 26	-0.54 Dactylitic digits	Standard Deviation 1.77
Participants With Rheumatoid Arthritis	Change From Baseline in Inflamed Dactylitic Digits at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Change at Week 39	-0.61 Dactylitic digits	Standard Deviation 1.53
Participants With Rheumatoid Arthritis	Change From Baseline in Inflamed Dactylitic Digits at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Change at Week 52	-0.69 Dactylitic digits	Standard Deviation 1.58
Participants With Rheumatoid Arthritis	Change From Baseline in Inflamed Dactylitic Digits at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Change at Week 65	-0.50 Dactylitic digits	Standard Deviation 2.08
Participants With Rheumatoid Arthritis	Change From Baseline in Inflamed Dactylitic Digits at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Change at Week 78	-0.38 Dactylitic digits	Standard Deviation 1.4
Participants With Rheumatoid Arthritis	Change From Baseline in Inflamed Dactylitic Digits at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Change at Week 104	-0.61 Dactylitic digits	Standard Deviation 1.47
Participants With Rheumatoid Arthritis	Change From Baseline in Inflamed Dactylitic Digits at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Change at Week 130	-0.63 Dactylitic digits	Standard Deviation 1.96
Participants With Rheumatoid Arthritis	Change From Baseline in Inflamed Dactylitic Digits at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Change at Week 156	-0.63 Dactylitic digits	Standard Deviation 1.72

Secondary

Change From Baseline in Nail Involvement at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis

In this outcome measure change in number of nails affected by psoriatic arthritis at specified week compared to baseline is reported. Nails included both finger nails and toe nails.

Time frame: Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants With Rheumatoid Arthritis	Change From Baseline in Nail Involvement at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Baseline	3.18 Nails	Standard Deviation 4.99
Participants With Rheumatoid Arthritis	Change From Baseline in Nail Involvement at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Change at Week 13	-0.98 Nails	Standard Deviation 3.58
Participants With Rheumatoid Arthritis	Change From Baseline in Nail Involvement at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Change at Week 26	-1.64 Nails	Standard Deviation 4.38
Participants With Rheumatoid Arthritis	Change From Baseline in Nail Involvement at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Change at Week 39	-1.75 Nails	Standard Deviation 4.55
Participants With Rheumatoid Arthritis	Change From Baseline in Nail Involvement at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Change at Week 52	-2.09 Nails	Standard Deviation 5.04
Participants With Rheumatoid Arthritis	Change From Baseline in Nail Involvement at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Change at Week 65	-2.38 Nails	Standard Deviation 4.89
Participants With Rheumatoid Arthritis	Change From Baseline in Nail Involvement at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Change at Week 78	-1.79 Nails	Standard Deviation 4.3
Participants With Rheumatoid Arthritis	Change From Baseline in Nail Involvement at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Change at Week 104	-1.98 Nails	Standard Deviation 5.81
Participants With Rheumatoid Arthritis	Change From Baseline in Nail Involvement at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Change at Week 130	-1.12 Nails	Standard Deviation 4.75
Participants With Rheumatoid Arthritis	Change From Baseline in Nail Involvement at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis	Change at Week 156	-1.38 Nails	Standard Deviation 5.11

Secondary

Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156

PtGA: participant assessed their disease activity using a 100 mm visual analog scale ranging from 0 = very good to 100 = worst. Higher scores indicate worse health status.

Time frame: Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants With Rheumatoid Arthritis	Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Baseline	54.69 millimeter	Standard Deviation 24.91
Participants With Rheumatoid Arthritis	Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 13	-13.55 millimeter	Standard Deviation 27.17
Participants With Rheumatoid Arthritis	Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 26	-17.30 millimeter	Standard Deviation 29.43
Participants With Rheumatoid Arthritis	Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 39	-18.09 millimeter	Standard Deviation 28.13
Participants With Rheumatoid Arthritis	Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 52	-19.38 millimeter	Standard Deviation 28.84
Participants With Rheumatoid Arthritis	Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 65	-22.52 millimeter	Standard Deviation 29.15
Participants With Rheumatoid Arthritis	Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 104	-22.68 millimeter	Standard Deviation 26.87
Participants With Rheumatoid Arthritis	Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 130	-23.75 millimeter	Standard Deviation 27.23
Participants With Rheumatoid Arthritis	Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 156	-26.30 millimeter	Standard Deviation 27.39
Participants With Rheumatoid Arthritis	Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 78	-22.24 millimeter	Standard Deviation 30.34
Participants With Psoriatic Arthritis	Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 130	-23.10 millimeter	Standard Deviation 29.21
Participants With Psoriatic Arthritis	Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Baseline	56.99 millimeter	Standard Deviation 24.57
Participants With Psoriatic Arthritis	Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 65	-22.74 millimeter	Standard Deviation 28.75
Participants With Psoriatic Arthritis	Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 13	-17.13 millimeter	Standard Deviation 28.34
Participants With Psoriatic Arthritis	Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 78	-24.59 millimeter	Standard Deviation 31.73
Participants With Psoriatic Arthritis	Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 26	-19.32 millimeter	Standard Deviation 27.37
Participants With Psoriatic Arthritis	Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 104	-20.59 millimeter	Standard Deviation 31.57
Participants With Psoriatic Arthritis	Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 39	-21.58 millimeter	Standard Deviation 28.74
Participants With Psoriatic Arthritis	Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 156	-21.24 millimeter	Standard Deviation 30.14
Participants With Psoriatic Arthritis	Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 52	-22.55 millimeter	Standard Deviation 30.03

Secondary

Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156

VAS: participants placed a mark indicating the intensity of their pain on a scale of 0 (no pain) to 100 mm (worst possible pain). Higher scores indicate greater level of pain.

Time frame: Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants With Rheumatoid Arthritis	Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 104	-23.46 millimeter	Standard Deviation 29.01
Participants With Rheumatoid Arthritis	Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 78	-22.58 millimeter	Standard Deviation 32.12
Participants With Rheumatoid Arthritis	Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 39	-18.38 millimeter	Standard Deviation 29.91
Participants With Rheumatoid Arthritis	Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Baseline	55.93 millimeter	Standard Deviation 26.26
Participants With Rheumatoid Arthritis	Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 130	-24.67 millimeter	Standard Deviation 28.75
Participants With Rheumatoid Arthritis	Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 13	-15.03 millimeter	Standard Deviation 28.5
Participants With Rheumatoid Arthritis	Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 65	-22.83 millimeter	Standard Deviation 30.95
Participants With Rheumatoid Arthritis	Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 26	-18.56 millimeter	Standard Deviation 29.83
Participants With Rheumatoid Arthritis	Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 156	-26.88 millimeter	Standard Deviation 28.77
Participants With Rheumatoid Arthritis	Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 52	-19.73 millimeter	Standard Deviation 31.02
Participants With Psoriatic Arthritis	Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 156	-18.33 millimeter	Standard Deviation 31.13
Participants With Psoriatic Arthritis	Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 65	-22.40 millimeter	Standard Deviation 29.74
Participants With Psoriatic Arthritis	Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 78	-24.91 millimeter	Standard Deviation 31.69
Participants With Psoriatic Arthritis	Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 104	-21.09 millimeter	Standard Deviation 32.67
Participants With Psoriatic Arthritis	Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 130	-21.67 millimeter	Standard Deviation 29.18
Participants With Psoriatic Arthritis	Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 52	-22.24 millimeter	Standard Deviation 30.57
Participants With Psoriatic Arthritis	Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 26	-19.01 millimeter	Standard Deviation 27.51
Participants With Psoriatic Arthritis	Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Baseline	57.69 millimeter	Standard Deviation 25.14
Participants With Psoriatic Arthritis	Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 13	-18.20 millimeter	Standard Deviation 27.96
Participants With Psoriatic Arthritis	Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 39	-21.84 millimeter	Standard Deviation 29.62

Secondary

Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156

PhyGA: physician marked intensity of participants' pain on a visual analogue scale of 0 (no disease activity) to 100 mm (worst possible condition). Higher scores indicate greater level of disease activity.

Time frame: Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants With Rheumatoid Arthritis	Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 104	-37.10 millimeter	Standard Deviation 23.18
Participants With Rheumatoid Arthritis	Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 13	-24.49 millimeter	Standard Deviation 22.98
Participants With Rheumatoid Arthritis	Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 26	-29.22 millimeter	Standard Deviation 24.42
Participants With Rheumatoid Arthritis	Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 39	-30.67 millimeter	Standard Deviation 23.92
Participants With Rheumatoid Arthritis	Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 52	-31.78 millimeter	Standard Deviation 24.74
Participants With Rheumatoid Arthritis	Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 65	-34.07 millimeter	Standard Deviation 24.83
Participants With Rheumatoid Arthritis	Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 78	-35.88 millimeter	Standard Deviation 25.29
Participants With Rheumatoid Arthritis	Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 130	-37.11 millimeter	Standard Deviation 22.96
Participants With Rheumatoid Arthritis	Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 156	-40.09 millimeter	Standard Deviation 22.39
Participants With Rheumatoid Arthritis	Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Baseline	57.28 millimeter	Standard Deviation 19.38
Participants With Psoriatic Arthritis	Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 130	-33.98 millimeter	Standard Deviation 22.19
Participants With Psoriatic Arthritis	Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Baseline	55.73 millimeter	Standard Deviation 19.9
Participants With Psoriatic Arthritis	Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 65	-34.37 millimeter	Standard Deviation 24.02
Participants With Psoriatic Arthritis	Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 13	-24.97 millimeter	Standard Deviation 23.29
Participants With Psoriatic Arthritis	Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 78	-35.87 millimeter	Standard Deviation 23.66
Participants With Psoriatic Arthritis	Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 26	-28.54 millimeter	Standard Deviation 24.28
Participants With Psoriatic Arthritis	Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 104	-34.87 millimeter	Standard Deviation 21.22
Participants With Psoriatic Arthritis	Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 39	-32.06 millimeter	Standard Deviation 24.46
Participants With Psoriatic Arthritis	Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 156	-34.75 millimeter	Standard Deviation 22.55
Participants With Psoriatic Arthritis	Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156	Change at Week 52	-34.36 millimeter	Standard Deviation 22.72

Secondary

Change From Baseline in Simple Disease Activity Index (SDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis

SDAI was calculated from tender and swollen joints using 28 joint count, participant global assessment (PtGA), physician global assessment and (PhyGA) and CRP (in mg/L). PtGA and PhyGA both were assessed on 0-100 mm VAS scale, where higher scores indicated greater affection due to disease activity. SDAI total score ranged from 0 to 86, where higher scores indicated higher disease activity. SDAI score of \<=11 indicates low disease activity and a score of \<=3.3 indicates remission.

Time frame: Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants With Rheumatoid Arthritis	Change From Baseline in Simple Disease Activity Index (SDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Change at Week 52	-17.70 Units on a scale	Standard Deviation 47.4
Participants With Rheumatoid Arthritis	Change From Baseline in Simple Disease Activity Index (SDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Change at Week 65	-18.77 Units on a scale	Standard Deviation 49.86
Participants With Rheumatoid Arthritis	Change From Baseline in Simple Disease Activity Index (SDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Baseline	35.88 Units on a scale	Standard Deviation 198.26
Participants With Rheumatoid Arthritis	Change From Baseline in Simple Disease Activity Index (SDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Change at Week 13	-20.62 Units on a scale	Standard Deviation 225.74
Participants With Rheumatoid Arthritis	Change From Baseline in Simple Disease Activity Index (SDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Change at Week 26	-26.04 Units on a scale	Standard Deviation 248.89
Participants With Rheumatoid Arthritis	Change From Baseline in Simple Disease Activity Index (SDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Change at Week 39	-16.00 Units on a scale	Standard Deviation 45.07
Participants With Rheumatoid Arthritis	Change From Baseline in Simple Disease Activity Index (SDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Change at Week 78	-19.02 Units on a scale	Standard Deviation 51.83
Participants With Rheumatoid Arthritis	Change From Baseline in Simple Disease Activity Index (SDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Change at Week 103	-18.08 Units on a scale	Standard Deviation 15.07
Participants With Rheumatoid Arthritis	Change From Baseline in Simple Disease Activity Index (SDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Change at Week 130	-17.33 Units on a scale	Standard Deviation 17.19
Participants With Rheumatoid Arthritis	Change From Baseline in Simple Disease Activity Index (SDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis	Change at Week 156	-18.85 Units on a scale	Standard Deviation 14.06

Secondary

Change From Baseline in Total Erosion Score at End of Phase 1 (Week 78) and Phase 2 (Week 156)

Total erosion score as per van der Hejde method consisted of 2 dimensions: a) hands (32 erosion locations, each location graded from 0 \[no erosion\] to 5 \[maximum severity\], sum of grading of each location resulted in score of 0 to 160); and b) feet (12 erosion locations, each location graded from 0 \[no erosion\] to 10 \[maximum severity\], sum of grading of each location resulted in score of 0 to 120). Sum of erosion scores of hand (0 to 160) and feet (0 to 120) gave a total erosion score as 0 to 280, where 0 was no erosion at all and 280 was worst possible condition, higher scores indicated severe joint destruction.

Time frame: Baseline, Week 78, 156

Population: Efficacy analysis set included participants who received at least 1 dose of Etanercept and had Rx1 and Rx2 or had Rx1 and Rx3. Here, Overall Number of Participants Analyzed = number of participants evaluable for this outcome measure and Number Analyzed = number of participants evaluable for the specified time points.

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants With Rheumatoid Arthritis	Change From Baseline in Total Erosion Score at End of Phase 1 (Week 78) and Phase 2 (Week 156)	Baseline	11.1 Units on a scale	Standard Deviation 23.8
Participants With Rheumatoid Arthritis	Change From Baseline in Total Erosion Score at End of Phase 1 (Week 78) and Phase 2 (Week 156)	Change at Week 78	-0.1 Units on a scale	Standard Deviation 4.1
Participants With Rheumatoid Arthritis	Change From Baseline in Total Erosion Score at End of Phase 1 (Week 78) and Phase 2 (Week 156)	Change at Week 156	0.0 Units on a scale	Standard Deviation 5.7
Participants With Psoriatic Arthritis	Change From Baseline in Total Erosion Score at End of Phase 1 (Week 78) and Phase 2 (Week 156)	Baseline	4.6 Units on a scale	Standard Deviation 11.9
Participants With Psoriatic Arthritis	Change From Baseline in Total Erosion Score at End of Phase 1 (Week 78) and Phase 2 (Week 156)	Change at Week 78	-0.3 Units on a scale	Standard Deviation 3.1
Participants With Psoriatic Arthritis	Change From Baseline in Total Erosion Score at End of Phase 1 (Week 78) and Phase 2 (Week 156)	Change at Week 156	0.2 Units on a scale	Standard Deviation 6.5

Secondary

Change From Baseline in Total Joint Space Narrow Score at End of Phase 1 (Week 78) and Phase 2 (Week 156)

Total joint space narrow score as per van der Hejde method consisted of 2 dimensions: a) hands (30 joint space locations, each location graded from 0 \[normal joint space\] to 4 \[bony ankylosis\], sum of grading of each location resulted in score of 0 to 120); and b) feet (12 erosion locations, each location graded from 0 \[no erosion\] to 4 \[bony ankylosis\], sum of grading of each location resulted in score of 0 to 48). Sum of joint space narrow scores of hand (0 to 120) and feet (0 to 48) gave a total joint space narrow score as 0 to 168, where 0 was normal joint space and 168 was maximum narrowing in joints, higher scores indicated severe joint destruction.

Time frame: Baseline, Week 78, 156

Population: Efficacy analysis set included participants who received at least 1 dose of Etanercept and had Rx1 and Rx2 or have Rx1 and Rx3. Here, Overall Number of Participants Analyzed = number of participants evaluable for this outcome measure and Number Analyzed = number of participants evaluable for the specified time points.

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants With Rheumatoid Arthritis	Change From Baseline in Total Joint Space Narrow Score at End of Phase 1 (Week 78) and Phase 2 (Week 156)	Baseline	14.0 Units on a scale	Standard Deviation 19.9
Participants With Rheumatoid Arthritis	Change From Baseline in Total Joint Space Narrow Score at End of Phase 1 (Week 78) and Phase 2 (Week 156)	Change at Week 78	0.7 Units on a scale	Standard Deviation 4.3
Participants With Rheumatoid Arthritis	Change From Baseline in Total Joint Space Narrow Score at End of Phase 1 (Week 78) and Phase 2 (Week 156)	Change at Week 156	1.4 Units on a scale	Standard Deviation 5.9
Participants With Psoriatic Arthritis	Change From Baseline in Total Joint Space Narrow Score at End of Phase 1 (Week 78) and Phase 2 (Week 156)	Baseline	10.0 Units on a scale	Standard Deviation 15
Participants With Psoriatic Arthritis	Change From Baseline in Total Joint Space Narrow Score at End of Phase 1 (Week 78) and Phase 2 (Week 156)	Change at Week 78	-0.1 Units on a scale	Standard Deviation 3.7
Participants With Psoriatic Arthritis	Change From Baseline in Total Joint Space Narrow Score at End of Phase 1 (Week 78) and Phase 2 (Week 156)	Change at Week 156	0.6 Units on a scale	Standard Deviation 3.1

Secondary

Duration of Morning Stiffness in Participants With Temporary Rigidity

Rigidity was temporary when 'Yes' was given for the question if daily activities could be done without stiffness; rigidity was permanent when 'No' was given for the question if daily activities could be done without stiffness.

Time frame: Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156

Arm	Measure	Group	Value (MEDIAN)
Participants With Rheumatoid Arthritis	Duration of Morning Stiffness in Participants With Temporary Rigidity	Week 26	0.50 Hours
Participants With Rheumatoid Arthritis	Duration of Morning Stiffness in Participants With Temporary Rigidity	Week 13	0.50 Hours
Participants With Rheumatoid Arthritis	Duration of Morning Stiffness in Participants With Temporary Rigidity	Week 78	0.38 Hours
Participants With Rheumatoid Arthritis	Duration of Morning Stiffness in Participants With Temporary Rigidity	Week 39	0.50 Hours
Participants With Rheumatoid Arthritis	Duration of Morning Stiffness in Participants With Temporary Rigidity	Week 104	0.25 Hours
Participants With Rheumatoid Arthritis	Duration of Morning Stiffness in Participants With Temporary Rigidity	Baseline	1.00 Hours
Participants With Rheumatoid Arthritis	Duration of Morning Stiffness in Participants With Temporary Rigidity	Week 130	0.25 Hours
Participants With Rheumatoid Arthritis	Duration of Morning Stiffness in Participants With Temporary Rigidity	Week 52	0.50 Hours
Participants With Rheumatoid Arthritis	Duration of Morning Stiffness in Participants With Temporary Rigidity	Week 156	0.25 Hours
Participants With Rheumatoid Arthritis	Duration of Morning Stiffness in Participants With Temporary Rigidity	Week 65	0.50 Hours
Participants With Psoriatic Arthritis	Duration of Morning Stiffness in Participants With Temporary Rigidity	Week 156	0.33 Hours
Participants With Psoriatic Arthritis	Duration of Morning Stiffness in Participants With Temporary Rigidity	Baseline	1.00 Hours
Participants With Psoriatic Arthritis	Duration of Morning Stiffness in Participants With Temporary Rigidity	Week 13	0.50 Hours
Participants With Psoriatic Arthritis	Duration of Morning Stiffness in Participants With Temporary Rigidity	Week 26	0.50 Hours
Participants With Psoriatic Arthritis	Duration of Morning Stiffness in Participants With Temporary Rigidity	Week 39	0.50 Hours
Participants With Psoriatic Arthritis	Duration of Morning Stiffness in Participants With Temporary Rigidity	Week 52	0.50 Hours
Participants With Psoriatic Arthritis	Duration of Morning Stiffness in Participants With Temporary Rigidity	Week 65	0.25 Hours
Participants With Psoriatic Arthritis	Duration of Morning Stiffness in Participants With Temporary Rigidity	Week 78	0.46 Hours
Participants With Psoriatic Arthritis	Duration of Morning Stiffness in Participants With Temporary Rigidity	Week 104	0.25 Hours
Participants With Psoriatic Arthritis	Duration of Morning Stiffness in Participants With Temporary Rigidity	Week 130	0.50 Hours

Secondary

Effect on Normalized Radiographic Progression With Respect to Baseline Disease Activity Score-28 (DAS-28)

Effect on radiographic progression with respect to baseline DAS-28 was evaluated using ANOVA model. Dependent variable was normalized progression under treatment with Etanercept and independent variable was baseline DAS-28. Baseline DAS-28 is less than or equal to (\<=) 5.1 or \>5.1. DAS28: score range from 0 (none) to 9.4 (extreme disease activity); low =2.6 to 3.2, moderate =3.2 to 5.1, and high disease activity \>5.1. DAS28 score of \<2.6 indicates disease remission.

Time frame: Baseline up to Week 78

Population: Efficacy analysis set for Phase 1 included participants who received at least 1 dose of Etanercept and had Rx1 and Rx2. Here, Overall Number of Participants Analyzed = number of participants evaluable for this outcome measure and Number Analyzed = number of participants evaluable for the specified rows.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Participants With Rheumatoid Arthritis	Effect on Normalized Radiographic Progression With Respect to Baseline Disease Activity Score-28 (DAS-28)	Baseline DAS-28 <= 5.1	0.716 Scores per year
Participants With Rheumatoid Arthritis	Effect on Normalized Radiographic Progression With Respect to Baseline Disease Activity Score-28 (DAS-28)	Baseline DAS-28 > 5.1	0.170 Scores per year
Participants With Psoriatic Arthritis	Effect on Normalized Radiographic Progression With Respect to Baseline Disease Activity Score-28 (DAS-28)	Baseline DAS-28 <= 5.1	-0.314 Scores per year
Participants With Psoriatic Arthritis	Effect on Normalized Radiographic Progression With Respect to Baseline Disease Activity Score-28 (DAS-28)	Baseline DAS-28 > 5.1	-0.507 Scores per year

Comparison: Statistical analysis (P value) composite for all categories.p-value: 0.364ANOVA

Comparison: Statistical analysis (P value) composite for all categories.p-value: 0.849ANOVA

Secondary

Effect on Normalized Radiographic Progression With Respect to Baseline Positivity of Anti-citrullinated Protein Antibody (ACPA) - Rheumatoid Factor (RF)

Effect on normalized radiographic progression with respect to ACPA-RF was evaluated using an analysis of variance (ANOVA) model. Dependent variable was normalized progression under treatment with Etanercept and independent variable was groups of positive testing of ACPA and RF at baseline.

Time frame: Baseline up to Week 78

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Participants With Rheumatoid Arthritis	Effect on Normalized Radiographic Progression With Respect to Baseline Positivity of Anti-citrullinated Protein Antibody (ACPA) - Rheumatoid Factor (RF)	ACPA and RF negative	1.326 Scores per year
Participants With Rheumatoid Arthritis	Effect on Normalized Radiographic Progression With Respect to Baseline Positivity of Anti-citrullinated Protein Antibody (ACPA) - Rheumatoid Factor (RF)	ACPA or RF positive	1.075 Scores per year
Participants With Rheumatoid Arthritis	Effect on Normalized Radiographic Progression With Respect to Baseline Positivity of Anti-citrullinated Protein Antibody (ACPA) - Rheumatoid Factor (RF)	ACPA and RF positive	0.087 Scores per year
Participants With Psoriatic Arthritis	Effect on Normalized Radiographic Progression With Respect to Baseline Positivity of Anti-citrullinated Protein Antibody (ACPA) - Rheumatoid Factor (RF)	ACPA and RF negative	-1.142 Scores per year
Participants With Psoriatic Arthritis	Effect on Normalized Radiographic Progression With Respect to Baseline Positivity of Anti-citrullinated Protein Antibody (ACPA) - Rheumatoid Factor (RF)	ACPA or RF positive	2.448 Scores per year
Participants With Psoriatic Arthritis	Effect on Normalized Radiographic Progression With Respect to Baseline Positivity of Anti-citrullinated Protein Antibody (ACPA) - Rheumatoid Factor (RF)	ACPA and RF positive	3.370 Scores per year

Comparison: Statistical analysis (P value) composite for all categories.p-value: 0.106ANOVA

Comparison: Statistical analysis (P value) composite for all categories.p-value: 0.181ANOVA

Secondary

Effect on Normalized Radiographic Progression With Respect to Baseline Usage of Concomitant Medication

Effect on normalized radiographic progression with respect to use of concomitant medication at baseline was evaluated using an ANOVA model. Dependent variable was normalized progression under treatment with Etanercept and independent variable was groups of concomitant medication as found among the medication given concomitantly during study that is recorded at baseline.

Time frame: Baseline up to Week 78

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Participants With Rheumatoid Arthritis	Effect on Normalized Radiographic Progression With Respect to Baseline Usage of Concomitant Medication	Concomitant Medication at baseline: Yes	0.749 Scores per year
Participants With Rheumatoid Arthritis	Effect on Normalized Radiographic Progression With Respect to Baseline Usage of Concomitant Medication	Concomitant Medication at baseline: No	-0.978 Scores per year
Participants With Psoriatic Arthritis	Effect on Normalized Radiographic Progression With Respect to Baseline Usage of Concomitant Medication	Concomitant Medication at baseline: Yes	-0.339 Scores per year
Participants With Psoriatic Arthritis	Effect on Normalized Radiographic Progression With Respect to Baseline Usage of Concomitant Medication	Concomitant Medication at baseline: No	-0.370 Scores per year

Comparison: Statistical analysis (P value) composite for all categories.p-value: 0.015ANOVA

Comparison: Statistical analysis (P value) composite for all categories.p-value: 0.969ANOVA

Secondary

Effect on Normalized Radiographic Progression With Respect to Previous Treatment With Biologics

Effect on normalized radiographic progression of previous treatment with biologics was evaluated using an ANOVA model. Dependent variable was normalized progression under treatment with Etanercept and independent variable was previous treatment with biologics.

Time frame: Baseline up to Week 78

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Participants With Rheumatoid Arthritis	Effect on Normalized Radiographic Progression With Respect to Previous Treatment With Biologics	Previous treatment with biologics	0.235 Scores per year
Participants With Rheumatoid Arthritis	Effect on Normalized Radiographic Progression With Respect to Previous Treatment With Biologics	No previous treatment with biologics	0.621 Scores per year
Participants With Psoriatic Arthritis	Effect on Normalized Radiographic Progression With Respect to Previous Treatment With Biologics	Previous treatment with biologics	-0.986 Scores per year
Participants With Psoriatic Arthritis	Effect on Normalized Radiographic Progression With Respect to Previous Treatment With Biologics	No previous treatment with biologics	-0.170 Scores per year

Comparison: Statistical analysis (P value) composite for all categories.p-value: 0.489ANOVA

Comparison: Statistical analysis (P value) composite for all categories.p-value: 0.386ANOVA

Secondary

Linear Relationship Between Normalized Radiographic Progression and Disease Duration

Linear relationship between radiographic progression and disease duration was evaluated using a linear regression model. Dependent variable was normalized progression under treatment with Etanercept and independent variable was disease duration.

Time frame: Baseline up to Week 78

Population: Efficacy analysis set for Phase 1 included participants who received at least 1 dose of Etanercept and had Rx1 and Rx2. Here, Overall Number of Participants Analyzed signifies number of participants evaluable for this outcome measure.

Arm	Measure	Value (NUMBER)
Participants With Rheumatoid Arthritis	Linear Relationship Between Normalized Radiographic Progression and Disease Duration	-0.012 Regression coefficient
Participants With Psoriatic Arthritis	Linear Relationship Between Normalized Radiographic Progression and Disease Duration	-0.050 Regression coefficient

p-value: 0.675Regression, Linear

p-value: 0.357Regression, Linear

Secondary

Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis

Participants with psoriatic arthritis were distributed in following different classes depending upon percentage (%) of BSA affected: 1) less than (\<) 3 %, 2) 3-10%, 3) 11-20% and 4) \>20%. Psoriatic arthritis affecting \<3% BSA was considered as mild, 3 to 10 % as moderate and \>10 percent as severe.

Time frame: Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 13	>20%	13 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 39	>20%	2 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 104	11-20%	2 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Baseline	<3%	203 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Baseline	3-10%	123 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Baseline	11-20%	41 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Baseline	>20%	20 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 13	<3%	247 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 13	3-10%	82 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 13	11-20%	28 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 26	<3%	233 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 26	3-10%	63 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 26	11-20%	14 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 26	>20%	6 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 39	<3%	210 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 39	3-10%	35 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 39	11-20%	15 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 52	<3%	196 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 52	3-10%	37 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 52	11-20%	10 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 52	>20%	3 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 65	<3%	176 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 65	3-10%	33 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 65	11-20%	4 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 65	>20%	2 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 78	<3%	182 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 78	3-10%	23 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 78	11-20%	5 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 78	>20%	1 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 104	<3%	80 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 104	3-10%	12 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 104	>20%	2 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 130	<3%	75 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 130	3-10%	9 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 130	11-20%	4 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 130	>20%	1 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 156	<3%	74 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 156	3-10%	8 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 156	11-20%	2 Participants
Participants With Rheumatoid Arthritis	Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis	Week 156	>20%	1 Participants

Secondary

Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)

EQ-5D: participant rated questionnaire to assess generic health status in two parts: single utility score and visual analog scale. For utility score, participants rated their current health state on 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression with each dimension having three levels of function: 1 indicates no problem; 2 indicates some problem; 3 indicates extreme problem.

Time frame: Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Self-care	Some problems	61 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Mobility	Some problems	714 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Mobility	Extreme problems	3 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Mobility	No data	10 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Self-care	No problems	798 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Self-care	Some problems	423 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Self-care	Extreme problems	37 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Self-care	No data	15 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Usual Activities	No problems	326 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Usual Activities	Some problems	887 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Usual Activities	Extreme problems	51 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Usual Activities	No data	9 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Pain/Discomfort	No problems	67 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Pain/Discomfort	Some problems	817 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Pain/Discomfort	Extreme problems	380 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Pain/Discomfort	No data	9 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Anxiety/Depression	No problems	693 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Anxiety/Depression	Some problems	515 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Anxiety/Depression	Extreme problems	56 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Anxiety/Depression	No data	9 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Mobility	No problems	640 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Mobility	Some problems	586 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Mobility	Extreme problems	4 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Mobility	No data	10 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Self-care	No problems	867 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Self-care	Some problems	329 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Self-care	Extreme problems	34 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Self-care	No data	10 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Usual Activities	No problems	480 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Usual Activities	Some problems	699 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Usual Activities	Extreme problems	50 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Usual Activities	No data	11 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Pain/Discomfort	No problems	162 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Pain/Discomfort	Some problems	903 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Pain/Discomfort	Extreme problems	164 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Pain/Discomfort	No data	11 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13:Anxiety/ Depression	Some problems	427 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13:Anxiety/ Depression	Extreme problems	48 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13:Anxiety/ Depression	No data	14 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Mobility	No problems	558 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Mobility	Some problems	461 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Mobility	No data	9 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Self-care	No problems	733 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Self-care	Some problems	267 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Self-care	Extreme problems	22 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Self-care	No data	9 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Usual Activities	No problems	433 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Usual Activities	Some problems	550 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Usual Activities	Extreme problems	38 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Usual Activities	No data	10 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Pain/Discomfort	No problems	181 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Pain/Discomfort	Some problems	733 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Pain/Discomfort	Extreme problems	105 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Pain/Discomfort	No data	12 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Anxiety/Depression	No problems	641 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Anxiety/Depression	Some problems	348 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Anxiety/Depression	Extreme problems	32 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Anxiety/Depression	No data	10 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Mobility	Some problems	391 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Mobility	No data	4 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Self-care	No problems	664 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Self-care	Some problems	212 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Self-care	Extreme problems	21 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Self-care	No data	7 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Usual Activities	No problems	402 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Usual Activities	Some problems	474 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Usual Activities	Extreme problems	24 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Usual Activities	No data	4 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Pain/Discomfort	No problems	161 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Pain/Discomfort	Some problems	641 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Pain/Discomfort	Extreme problems	98 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Pain/Discomfort	No data	4 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Anxiety/ Depression	No problems	576 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Anxiety/ Depression	Some problems	301 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Anxiety/ Depression	Extreme problems	22 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Anxiety/ Depression	No data	5 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Mobility	No problems	459 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Mobility	Some problems	346 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Mobility	Extreme problems	1 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Mobility	No data	5 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Self-care	Some problems	190 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Self-care	No data	5 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Usual Activities	No problems	400 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Usual Activities	Some problems	380 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Usual Activities	Extreme problems	26 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Usual Activities	No data	5 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Pain/Discomfort	No problems	153 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Pain/Discomfort	Some problems	577 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Pain/Discomfort	Extreme problems	73 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Anxiety/Depression	No problems	506 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Anxiety/Depression	Some problems	268 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Anxiety/Depression	No data	9 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Mobility	No problems	422 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Mobility	Some problems	292 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Mobility	Extreme problems	1 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Mobility	No data	4 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Self-care	No problems	525 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Self-care	Some problems	177 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Self-care	Extreme problems	11 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Self-care	No data	6 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Usual Activities	No problems	361 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Usual Activities	Some problems	331 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Usual Activities	Extreme problems	21 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Usual Activities	No data	6 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Pain/Discomfort	No problems	149 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Pain/Discomfort	Some problems	505 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Pain/Discomfort	Extreme problems	62 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Pain/Discomfort	No data	3 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Anxiety/ Depression	No problems	467 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Anxiety/ Depression	Extreme problems	23 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Anxiety/ Depression	No data	4 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Mobility	No problems	401 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Mobility	Some problems	286 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Mobility	Extreme problems	0 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Mobility	No data	5 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Self-care	No problems	527 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Self-care	Some problems	155 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Self-care	Extreme problems	6 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Self-care	No data	4 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Usual Activities	No problems	355 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Usual Activities	Some problems	316 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Usual Activities	Extreme problems	16 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Usual Activities	No data	5 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Pain/Discomfort	No problems	152 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Pain/Discomfort	Some problems	477 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Pain/Discomfort	Extreme problems	58 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Pain/Discomfort	No data	5 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Anxiety/Depression	No problems	455 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Anxiety/Depression	Some problems	211 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Anxiety/Depression	Extreme problems	20 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Anxiety/Depression	No data	6 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Mobility	No problems	167 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Mobility	Some problems	109 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13:Anxiety/ Depression	No problems	751 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Mobility	Extreme problems	3 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Mobility	No problems	506 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Mobility	Extreme problems	3 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Self-care	No problems	605 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Self-care	Extreme problems	11 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Pain/Discomfort	No data	8 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Anxiety/Depression	Extreme problems	28 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Anxiety/ Depression	Some problems	225 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Anxiety/Depression	No data	1 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Mobility	No problems	126 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Usual Activities	No data	1 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Pain/Discomfort	Some problems	149 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Pain/Discomfort	No data	2 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Anxiety/ Depression	Some problems	65 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Mobility	Extreme problems	2 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Mobility	No data	0 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Self-care	No problems	212 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Mobility	No problems	546 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Self-care	Extreme problems	4 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Self-care	No data	1 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Usual Activities	No problems	134 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Usual Activities	Some problems	141 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Usual Activities	Extreme problems	3 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Usual Activities	No data	0 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Pain/Discomfort	No problems	48 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Pain/Discomfort	Some problems	210 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Pain/Discomfort	Extreme problems	18 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Pain/Discomfort	No data	2 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Anxiety/ Depression	No problems	190 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Anxiety/ Depression	Some problems	80 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Anxiety/ Depression	Extreme problems	8 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Anxiety/ Depression	No data	0 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Mobility	No problems	144 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Mobility	Some problems	107 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Mobility	Extreme problems	0 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Mobility	No data	1 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Self-care	No problems	188 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Self-care	Some problems	58 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Self-care	Extreme problems	4 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Self-care	No data	2 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Usual Activities	No problems	126 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Usual Activities	Some problems	115 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Usual Activities	Extreme problems	9 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Usual Activities	No data	2 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Pain/Discomfort	No problems	55 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Pain/Discomfort	Some problems	174 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Pain/Discomfort	Extreme problems	22 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Pain/Discomfort	No data	1 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Anxiety/Depression	No problems	176 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Anxiety/Depression	Some problems	66 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Anxiety/Depression	Extreme problems	9 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Mobility	Some problems	86 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Mobility	Extreme problems	2 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Mobility	No data	1 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Self-care	No problems	156 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Self-care	Some problems	51 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Self-care	Extreme problems	7 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Self-care	No data	1 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Usual Activities	No problems	114 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Usual Activities	Some problems	92 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Usual Activities	Extreme problems	8 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Pain/Discomfort	No problems	49 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Pain/Discomfort	Extreme problems	15 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Anxiety/ Depression	No problems	143 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Anxiety/ Depression	Extreme problems	6 Participants
Participants With Rheumatoid Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Anxiety/ Depression	No data	1 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Self-care	Some problems	12 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Mobility	No problems	177 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Self-care	No data	2 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Mobility	Some problems	230 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Self-care	Some problems	12 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Mobility	Extreme problems	0 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Usual Activities	No problems	119 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Mobility	No data	4 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Usual Activities	No data	0 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Self-care	No problems	294 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Usual Activities	Some problems	100 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Self-care	Some problems	107 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Self-care	Extreme problems	1 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Self-care	Extreme problems	5 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Usual Activities	Extreme problems	3 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Self-care	No data	5 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Pain/Discomfort	Some problems	61 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Usual Activities	No problems	115 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Usual Activities	No data	2 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Usual Activities	Some problems	278 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Self-care	No data	3 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Pain/Discomfort	No problems	50 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Usual Activities	No data	3 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Pain/Discomfort	No problems	30 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Pain/Discomfort	No problems	19 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Pain/Discomfort	Some problems	147 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Pain/Discomfort	Some problems	264 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Usual Activities	No problems	68 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Pain/Discomfort	Extreme problems	125 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Pain/Discomfort	Extreme problems	23 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Pain/Discomfort	No data	3 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Self-care	Extreme problems	3 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Anxiety/Depression	No problems	218 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Pain/Discomfort	No data	4 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Anxiety/Depression	Some problems	167 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Usual Activities	Some problems	40 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Anxiety/Depression	Extreme problems	22 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Anxiety/ Depression	Some problems	62 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Anxiety/Depression	No data	4 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Pain/Discomfort	Some problems	71 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Mobility	No problems	213 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Anxiety/ Depression	Extreme problems	4 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Mobility	Some problems	183 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Usual Activities	Extreme problems	2 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Mobility	Extreme problems	1 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Anxiety/ Depression	No data	2 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Mobility	No data	5 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Anxiety/ Depression	No data	2 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Self-care	No problems	304 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Mobility	No problems	132 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Self-care	Some problems	85 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Usual Activities	No data	2 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Self-care	Extreme problems	7 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Mobility	Some problems	78 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Self-care	No data	6 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Pain/Discomfort	Extreme problems	6 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Usual Activities	No problems	166 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Mobility	Extreme problems	0 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Usual Activities	Some problems	222 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Pain/Discomfort	No problems	28 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Usual Activities	Extreme problems	10 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Mobility	No data	2 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Usual Activities	No data	4 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Self-care	No data	2 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Pain/Discomfort	No problems	59 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Self-care	No problems	178 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Pain/Discomfort	Some problems	77 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Pain/Discomfort	Extreme problems	69 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Self-care	Some problems	31 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Pain/Discomfort	No data	4 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13:Anxiety/ Depression	No problems	242 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Pain/Discomfort	No data	0 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13:Anxiety/ Depression	Some problems	142 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Self-care	Extreme problems	1 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Pain/Discomfort	Extreme problems	4 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13:Anxiety/ Depression	No data	4 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Self-care	No data	2 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Mobility	No problems	200 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Pain/Discomfort	Extreme problems	10 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Mobility	Some problems	137 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Mobility	Extreme problems	0 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Usual Activities	No problems	115 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Mobility	No data	7 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Pain/Discomfort	No data	3 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Self-care	No problems	267 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Usual Activities	Some problems	91 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Self-care	Some problems	66 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Anxiety/Depression	No problems	75 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Self-care	Extreme problems	5 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Usual Activities	Extreme problems	4 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Self-care	No data	6 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Anxiety/ Depression	No problems	86 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Usual Activities	No problems	156 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Usual Activities	No data	2 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Usual Activities	Some problems	171 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Usual Activities	No problems	55 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Usual Activities	Extreme problems	9 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Pain/Discomfort	No problems	55 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Usual Activities	No data	8 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Anxiety/ Depression	Some problems	21 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Pain/Discomfort	No problems	66 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Pain/Discomfort	Some problems	135 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Pain/Discomfort	Some problems	234 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Anxiety/Depression	Some problems	31 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Pain/Discomfort	Extreme problems	36 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Pain/Discomfort	Extreme problems	18 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Pain/Discomfort	No data	8 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Anxiety/ Depression	Extreme problems	3 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Anxiety/Depression	No problems	227 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Pain/Discomfort	No data	4 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Anxiety/Depression	Some problems	99 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Pain/Discomfort	No data	3 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Anxiety/Depression	Extreme problems	12 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Anxiety/Depression	No problems	152 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 26: Anxiety/Depression	No data	6 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Mobility	No problems	168 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Anxiety/ Depression	No data	2 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Mobility	Some problems	108 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Mobility	Extreme problems	0 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Anxiety/Depression	Some problems	50 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Mobility	No data	3 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Anxiety/Depression	Extreme problems	0 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Self-care	No problems	222 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Anxiety/Depression	Extreme problems	7 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Self-care	Some problems	49 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Mobility	No problems	69 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Self-care	Extreme problems	5 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 78: Anxiety/Depression	No data	3 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Self-care	No data	3 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Mobility	No problems	58 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Usual Activities	No problems	143 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Mobility	No problems	76 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Usual Activities	Some problems	131 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Mobility	Some problems	38 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Usual Activities	Extreme problems	3 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Baseline: Usual Activities	Extreme problems	15 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Usual Activities	No data	2 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13: Pain/Discomfort	Some problems	270 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Pain/Discomfort	No problems	67 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Usual Activities	Some problems	35 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Pain/Discomfort	Some problems	186 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 13:Anxiety/ Depression	Extreme problems	14 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Pain/Discomfort	Extreme problems	24 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Mobility	Extreme problems	0 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Pain/Discomfort	No data	2 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Mobility	Some problems	35 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Anxiety/ Depression	No problems	183 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Mobility	No data	0 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Anxiety/ Depression	Some problems	83 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Mobility	Some problems	92 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Anxiety/ Depression	Extreme problems	11 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Anxiety/ Depression	Extreme problems	4 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 39: Anxiety/ Depression	No data	2 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Self-care	No problems	86 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Mobility	No problems	158 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Mobility	Extreme problems	0 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Pain/Discomfort	No data	3 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Mobility	Extreme problems	0 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Anxiety/Depression	Some problems	73 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Mobility	No data	3 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Self-care	No problems	210 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Self-care	Some problems	20 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Self-care	Some problems	35 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Self-care	Extreme problems	5 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Anxiety/ Depression	No problems	156 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Self-care	No data	3 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Usual Activities	Extreme problems	3 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Usual Activities	No problems	130 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Self-care	Extreme problems	1 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Usual Activities	Some problems	115 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Anxiety/Depression	No data	1 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Usual Activities	Extreme problems	5 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Mobility	No data	2 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Usual Activities	No data	3 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Self-care	No data	0 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Pain/Discomfort	No problems	48 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Usual Activities	No data	2 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Pain/Discomfort	Some problems	185 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Anxiety/ Depression	No problems	68 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Pain/Discomfort	Extreme problems	17 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Usual Activities	No problems	63 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Anxiety/Depression	No problems	168 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Self-care	No problems	78 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Anxiety/Depression	Extreme problems	9 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Anxiety/ Depression	Some problems	21 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 52: Anxiety/Depression	No data	3 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Mobility	Some problems	34 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Mobility	No problems	141 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Usual Activities	Some problems	43 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Mobility	Some problems	81 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Mobility	Extreme problems	0 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Mobility	Extreme problems	0 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 156: Pain/Discomfort	No problems	21 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Mobility	No data	2 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Mobility	No data	2 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Self-care	No problems	183 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 130: Usual Activities	Extreme problems	1 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Self-care	Some problems	37 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 104: Self-care	No problems	96 Participants
Participants With Psoriatic Arthritis	Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)	Week 65: Self-care	Extreme problems	2 Participants

Secondary

Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)

In this outcome measure number of participants with use of glucocorticoids and DMARDs at baseline and specified weeks are reported. If participants used glucocorticoids and DMARDs, it was denoted by Yes and if they did not use, it was denoted by No. Data have been reported separately for glucocorticoids and DMARDs at specified weeks respectively, in 4 categories as: 1) Baseline: No and Specified Week: No, 2) Baseline: Yes and Specified Week: No, 3) Baseline: No and Specified Week: Yes, 4) Baseline: Yes and Specified Week: Yes.

Time frame: Baseline, Week 78, 156

Population: Full analysis set included all participants who received at least 1 dose of Etanercept and had at least 1 effectiveness measurement after start of treatment. Here, Number Analyzed = number of participants evaluable for the specified rows.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants With Rheumatoid Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	Glucocorticoids Usage Baseline Versus Week 156	Baseline: No and Specified Week: No	168 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	DMARDs Usage Baseline Versus Week 78	Baseline: No and Specified Week: No	124 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	Glucocorticoids Usage Baseline Versus Week 156	Baseline: Yes and Specified Week: No	91 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	Glucocorticoids Usage Baseline Versus Week 78	Baseline: No and Specified Week: No	499 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	Glucocorticoids Usage Baseline Versus Week 156	Baseline: No and Specified Week: Yes	20 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	DMARDs Usage Baseline Versus Week 78	Baseline: Yes and Specified Week: No	655 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	Glucocorticoids Usage Baseline Versus Week 156	Baseline: Yes and Specified Week: Yes	12 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	Glucocorticoids Usage Baseline Versus Week 78	Baseline: No and Specified Week: Yes	312 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	DMARDs Usage Baseline Versus Week 156	Baseline: No and Specified Week: No	33 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	DMARDs Usage Baseline Versus Week 78	Baseline: No and Specified Week: Yes	24 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	DMARDs Usage Baseline Versus Week 156	Baseline: Yes and Specified Week: No	234 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	Glucocorticoids Usage Baseline Versus Week 78	Baseline: Yes and Specified Week: Yes	293 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	DMARDs Usage Baseline Versus Week 156	Baseline: No and Specified Week: Yes	1 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	DMARDs Usage Baseline Versus Week 78	Baseline: Yes and Specified Week: Yes	478 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	DMARDs Usage Baseline Versus Week 156	Baseline: Yes and Specified Week: Yes	23 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	Glucocorticoids Usage Baseline Versus Week 78	Baseline: Yes and Specified Week: No	177 Participants
Participants With Psoriatic Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	DMARDs Usage Baseline Versus Week 156	Baseline: Yes and Specified Week: Yes	5 Participants
Participants With Psoriatic Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	Glucocorticoids Usage Baseline Versus Week 78	Baseline: No and Specified Week: No	258 Participants
Participants With Psoriatic Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	Glucocorticoids Usage Baseline Versus Week 78	Baseline: Yes and Specified Week: No	28 Participants
Participants With Psoriatic Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	Glucocorticoids Usage Baseline Versus Week 78	Baseline: Yes and Specified Week: Yes	58 Participants
Participants With Psoriatic Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	DMARDs Usage Baseline Versus Week 78	Baseline: No and Specified Week: No	133 Participants
Participants With Psoriatic Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	DMARDs Usage Baseline Versus Week 78	Baseline: Yes and Specified Week: No	139 Participants
Participants With Psoriatic Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	DMARDs Usage Baseline Versus Week 78	Baseline: No and Specified Week: Yes	17 Participants
Participants With Psoriatic Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	DMARDs Usage Baseline Versus Week 78	Baseline: Yes and Specified Week: Yes	124 Participants
Participants With Psoriatic Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	Glucocorticoids Usage Baseline Versus Week 156	Baseline: No and Specified Week: No	86 Participants
Participants With Psoriatic Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	Glucocorticoids Usage Baseline Versus Week 156	Baseline: Yes and Specified Week: No	18 Participants
Participants With Psoriatic Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	Glucocorticoids Usage Baseline Versus Week 156	Baseline: No and Specified Week: Yes	6 Participants
Participants With Psoriatic Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	Glucocorticoids Usage Baseline Versus Week 156	Baseline: Yes and Specified Week: Yes	6 Participants
Participants With Psoriatic Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	DMARDs Usage Baseline Versus Week 156	Baseline: No and Specified Week: No	39 Participants
Participants With Psoriatic Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	DMARDs Usage Baseline Versus Week 156	Baseline: Yes and Specified Week: No	71 Participants
Participants With Psoriatic Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	DMARDs Usage Baseline Versus Week 156	Baseline: No and Specified Week: Yes	1 Participants
Participants With Psoriatic Arthritis	Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)	Glucocorticoids Usage Baseline Versus Week 78	Baseline: No and Specified Week: Yes	69 Participants

Secondary

Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)

CDAI was calculated from tender and swollen joints using 28 joint count, PtGA and PhyGA. CDAI total score ranged from 0 to 76, where higher scores indicated higher disease activity. CDAI score of \<=10 indicates low disease activity and a score of \<= 2.8 indicates remission. SDAI was calculated from tender and swollen joints using 28 joint count, PtGA, PhyGA and CRP (in mg/L). SDAI total score ranged from 0 to 86, where higher scores indicated higher disease activity. SDAI score of \<=11 indicates low disease activity and a score of \<=3.3 indicates remission. PtGA and PhyGA both were assessed on 0-100 mm VAS scale, where higher scores indicated greater affection due to disease activity.

Time frame: Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156

Secondary

Percentage of Participants With Rheumatoid Arthritis, With Remission Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)

Time frame: Baseline, Week 13, 26, 39, 52, 65, 78, 104, 130, 156

Population: Full analysis set. Here, Overall Number of Participants Analyzed = number of participants evaluable for this outcome measure and Number Analyzed = number of participants evaluable for the specified time points. Data for this outcome measure was to be collected and evaluated only for participants with rheumatoid arthritis.

Secondary

Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Continuation of Treatment With Etanercept

In this outcome number of participants who participated or not participated in RUDI and PIT and impact of their participation in continuation or termination of treatment with Etanercept is reported. For participants whom data was not recorded is reported under category No Data.

Time frame: Baseline up to Week 156

Population: Full analysis set included all participants who received at least 1 dose of Etanercept and had at least 1 effectiveness measurement after start of treatment. Here, Overall Number of participants analyzed = number of participants evaluable for this measure and Number Analyzed = number of participants evaluable for the specified rows.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Continuation of Treatment With Etanercept	Rudi and PIT= Yes	Treatment Continued	207 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Continuation of Treatment With Etanercept	Rudi and PIT= Yes	Treatment Terminated	139 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Continuation of Treatment With Etanercept	Rudi and PIT= Yes	No Data	1 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Continuation of Treatment With Etanercept	Rudi and PIT= No	Treatment Continued	555 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Continuation of Treatment With Etanercept	Rudi and PIT= No	Treatment Terminated	335 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Continuation of Treatment With Etanercept	Rudi and PIT= No	No Data	4 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Continuation of Treatment With Etanercept	Rudi and PIT= No	Treatment Terminated	116 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Continuation of Treatment With Etanercept	Rudi and PIT= Yes	Treatment Continued	58 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Continuation of Treatment With Etanercept	Rudi and PIT= No	Treatment Continued	178 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Continuation of Treatment With Etanercept	Rudi and PIT= Yes	Treatment Terminated	48 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Continuation of Treatment With Etanercept	Rudi and PIT= No	No Data	0 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Continuation of Treatment With Etanercept	Rudi and PIT= Yes	No Data	0 Participants

Secondary

Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)

In this outcome number of participants who participated or not participated in RUDI and PIT and impact of their participation in quality of life parameters using EQ-5D health questionnaire is reported. For participants whom data was not recorded is reported under category No Data. EQ-5D: participant rated questionnaire to assess generic health status in two parts: single utility score and visual analog scale. For utility score, participants rated their current health state on 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression with each dimension having three levels of function: 1 indicates no problem; 2 indicates some problem; 3 indicates extreme problem.

Time frame: Baseline up to Week 156

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Self-care	Extreme problem	13 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Mobility	No problems	143 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Mobility	Extreme problem	2 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Mobility	No data	9 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Mobility	No problems	483 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Mobility	Some problems	394 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Mobility	Extreme problem	1 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Mobility	No data	9 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Self-care	No problems	213 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Self-care	Some problems	111 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Mobility	Some problems	191 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Self-care	No data	8 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Self-care	No problems	618 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Self-care	Some problems	244 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Self-care	Extreme problem	16 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Self-care	No data	9 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Usual Activities	No problems	113 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Usual Activities	Some problems	204 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Usual Activities	Extreme problem	19 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Usual Activities	No data	9 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Usual Activities	No problems	392 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Usual Activities	Some problems	456 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Usual Activities	Extreme problem	30 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Usual Activities	No data	9 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Pain/Discomfort	No problems	38 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Pain/Discomfort	Some problems	230 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Pain/Discomfort	Extreme problem	68 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Pain/Discomfort	No data	9 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Pain/Discomfort	No problems	155 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Pain/Discomfort	Some problems	611 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Pain/Discomfort	Extreme problem	112 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Pain/Discomfort	No data	9 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Anxiety/Depression	No problems	188 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Anxiety/Depression	Some problems	138 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Anxiety/Depression	Extreme problem	11 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Anxiety/Depression	No data	8 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Anxiety/Depression	No problems	544 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Anxiety/Depression	Some problems	300 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Anxiety/Depression	Extreme problem	34 Participants
Participants With Rheumatoid Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Anxiety/Depression	No data	9 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Anxiety/Depression	Some problems	88 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Usual Activities	No problems	142 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Mobility	No problems	50 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Mobility	Some problems	54 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Pain/Discomfort	Extreme problem	35 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Mobility	Extreme problem	0 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Usual Activities	Some problems	136 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Mobility	No data	2 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Anxiety/Depression	No data	3 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Mobility	No problems	167 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Usual Activities	Extreme problem	6 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Mobility	Some problems	117 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Pain/Discomfort	No data	8 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Mobility	Extreme problem	0 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Usual Activities	No data	8 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Mobility	No data	8 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Anxiety/Depression	No data	8 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Self-care	No problems	72 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Pain/Discomfort	No problems	17 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Self-care	Some problems	25 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Anxiety/Depression	No problems	63 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Self-care	Extreme problem	6 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Pain/Discomfort	Some problems	62 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Self-care	No data	3 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Anxiety/Depression	No problems	188 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Self-care	No problems	233 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Pain/Discomfort	Extreme problem	25 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Self-care	Some problems	47 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Anxiety/Depression	Some problems	34 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Self-care	Extreme problem	4 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Pain/Discomfort	No data	2 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Self-care	No data	8 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Anxiety/Depression	Extreme problem	8 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Usual Activities	No problems	39 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Pain/Discomfort	No problems	60 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Usual Activities	Some problems	58 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Anxiety/Depression	Extreme problem	6 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Usual Activities	Extreme problem	8 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= No: Pain/Discomfort	Some problems	189 Participants
Participants With Psoriatic Arthritis	Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)	Rudi and PIT= Yes: Usual Activities	No data	1 Participants

Other Pre-specified

Number of Participants Who Used Concomitant Medication

Number of participants who used medication other than Etanercept for relief of pain. It was determined by the treating physician.

Time frame: Baseline up to Week 156

Population: Safety analysis set included all patients who received at least 1 dose of Etanercept.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Participants With Rheumatoid Arthritis	Number of Participants Who Used Concomitant Medication	1284 Participants
Participants With Psoriatic Arthritis	Number of Participants Who Used Concomitant Medication	376 Participants
Participants With Unclear Diagnosis	Number of Participants Who Used Concomitant Medication	2 Participants

Other Pre-specified

Number of Participants With Discontinuation of Etanercept Treatment

Number of participants those who discontinued Etanercept treatment at Week 78 and 156 are reported in this outcome measure.

Time frame: Week 78, 156

Population: Safety analysis set included all patients who received at least 1 dose of Etanercept. Here, Number Analyzed signifies number of participants evaluable for specified time points.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants With Rheumatoid Arthritis	Number of Participants With Discontinuation of Etanercept Treatment	Week 78	57 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Discontinuation of Etanercept Treatment	Week 156	8 Participants
Participants With Psoriatic Arthritis	Number of Participants With Discontinuation of Etanercept Treatment	Week 78	18 Participants
Participants With Psoriatic Arthritis	Number of Participants With Discontinuation of Etanercept Treatment	Week 156	4 Participants
Participants With Unclear Diagnosis	Number of Participants With Discontinuation of Etanercept Treatment	Week 78	1 Participants

Other Pre-specified

Number of Participants With Pregnancy, Puerperium and Perinatal Conditions

In this outcome measure total number of participants with pregnancy, puerperium and perinatal conditions are reported. Pregnancy, puerperium and perinatal conditions included pregnancy, abortion, abortion spontaneous or premature baby.

Time frame: Baseline up to Week 156

Population: Safety analysis set included all patients who received at least 1 dose of Etanercept.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Participants With Rheumatoid Arthritis	Number of Participants With Pregnancy, Puerperium and Perinatal Conditions	4 Participants
Participants With Psoriatic Arthritis	Number of Participants With Pregnancy, Puerperium and Perinatal Conditions	1 Participants
Participants With Unclear Diagnosis	Number of Participants With Pregnancy, Puerperium and Perinatal Conditions	0 Participants

Other Pre-specified

Number of Participants With Results of Tolerability Assessment by Physician and Participant

Physicians and participants rated the tolerability of Etanercept treatment by means of a 4-point scale as: 1) very good, 2) good, 3) moderate and 4) insufficient.

Time frame: Week 78, 156

Population: Safety analysis set included all patients who received at least 1 dose of Etanercept. Here, Number Analyzed signifies number of participants evaluable for specified rows.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants With Rheumatoid Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Physician Assessment	Moderate	4 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 156: Physician Assessment	Insufficient	0 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Participant Assessment	Moderate	33 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Physician Assessment	Good	252 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 156: Physician Assessment	Moderate	1 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Participant Assessment	Insufficient	9 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 156: Participant Assessment	Moderate	4 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 156: Physician Assessment	Good	70 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 156: Physician Assessment	Very good	149 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Physician Assessment	Insufficient	4 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Physician Assessment	Very good	439 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 156: Participant Assessment	Good	89 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Participant Assessment	Very good	284 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 156: Participant Assessment	Insufficient	2 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 156: Participant Assessment	Very good	115 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Participant Assessment	Good	281 Participants
Participants With Psoriatic Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 156: Participant Assessment	Insufficient	0 Participants
Participants With Psoriatic Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Physician Assessment	Very good	146 Participants
Participants With Psoriatic Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Physician Assessment	Good	70 Participants
Participants With Psoriatic Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Physician Assessment	Moderate	2 Participants
Participants With Psoriatic Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Physician Assessment	Insufficient	2 Participants
Participants With Psoriatic Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Participant Assessment	Very good	96 Participants
Participants With Psoriatic Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Participant Assessment	Good	75 Participants
Participants With Psoriatic Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Participant Assessment	Moderate	12 Participants
Participants With Psoriatic Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Participant Assessment	Insufficient	0 Participants
Participants With Psoriatic Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 156: Physician Assessment	Very good	67 Participants
Participants With Psoriatic Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 156: Physician Assessment	Good	30 Participants
Participants With Psoriatic Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 156: Physician Assessment	Moderate	0 Participants
Participants With Psoriatic Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 156: Physician Assessment	Insufficient	0 Participants
Participants With Psoriatic Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 156: Participant Assessment	Very good	55 Participants
Participants With Psoriatic Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 156: Participant Assessment	Good	38 Participants
Participants With Psoriatic Arthritis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 156: Participant Assessment	Moderate	1 Participants
Participants With Unclear Diagnosis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Participant Assessment	Very good	1 Participants
Participants With Unclear Diagnosis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Physician Assessment	Very good	1 Participants
Participants With Unclear Diagnosis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Participant Assessment	Insufficient	0 Participants
Participants With Unclear Diagnosis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Physician Assessment	Insufficient	0 Participants
Participants With Unclear Diagnosis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Participant Assessment	Moderate	0 Participants
Participants With Unclear Diagnosis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Physician Assessment	Good	0 Participants
Participants With Unclear Diagnosis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Participant Assessment	Good	0 Participants
Participants With Unclear Diagnosis	Number of Participants With Results of Tolerability Assessment by Physician and Participant	Week 78: Physician Assessment	Moderate	0 Participants

Other Pre-specified

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)

Time frame: Baseline up to Week 156

Population: Safety analysis set included all patients who received at least 1 dose of Etanercept.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants With Rheumatoid Arthritis	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)	AEs	658 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)	SAEs	159 Participants
Participants With Psoriatic Arthritis	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)	AEs	190 Participants
Participants With Psoriatic Arthritis	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)	SAEs	47 Participants
Participants With Unclear Diagnosis	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)	AEs	1 Participants
Participants With Unclear Diagnosis	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)	SAEs	0 Participants

Other Pre-specified

Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events. AEs were classified according to the severity in 3 categories a)mild: AEs not interfered with participant's usual function b)moderate: AEs interfered to some extent with participant's usual function c)severe: AEs interfered significantly with participant's usual function. Participants may be counted in more than 1 category.

Time frame: Baseline up to Week 156

Population: Safety analysis set included all patients who received at least 1 dose of Etanercept. Here, Overall Number of Participants Analyzed signifies number of participants who had at least 1 treatment AE.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants With Rheumatoid Arthritis	Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity	Severe	172 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity	Mild	292 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity	No Data	36 Participants
Participants With Rheumatoid Arthritis	Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity	Moderate	377 Participants
Participants With Psoriatic Arthritis	Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity	Severe	52 Participants
Participants With Psoriatic Arthritis	Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity	Moderate	104 Participants
Participants With Psoriatic Arthritis	Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity	No Data	7 Participants
Participants With Psoriatic Arthritis	Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity	Mild	85 Participants
Participants With Unclear Diagnosis	Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity	No Data	1 Participants
Participants With Unclear Diagnosis	Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity	Mild	0 Participants
Participants With Unclear Diagnosis	Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity	Moderate	0 Participants
Participants With Unclear Diagnosis	Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity	Severe	0 Participants

Other Pre-specified

Number of Participants With Treatment-Emergent Treatment Related Adverse Events

Treatment-related AE was any untoward medical occurrence in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events. Relatedness to study treatment was assessed by the investigator.

Time frame: Baseline up to Week 156

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Participants With Rheumatoid Arthritis	Number of Participants With Treatment-Emergent Treatment Related Adverse Events	345 Participants
Participants With Psoriatic Arthritis	Number of Participants With Treatment-Emergent Treatment Related Adverse Events	100 Participants
Participants With Unclear Diagnosis	Number of Participants With Treatment-Emergent Treatment Related Adverse Events	1 Participants

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026

Arm	Measure	Group	Value (NUMBER)
Participants With Rheumatoid Arthritis	Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Week 103: CDAI	44.4 Percentage of participants
Participants With Rheumatoid Arthritis	Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Week 130: CDAI	41.5 Percentage of participants
Participants With Rheumatoid Arthritis	Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Baseline: SDAI	7.0 Percentage of participants
Participants With Rheumatoid Arthritis	Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Baseline: CDAI	7.0 Percentage of participants
Participants With Rheumatoid Arthritis	Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Week 13: CDAI	36.1 Percentage of participants
Participants With Rheumatoid Arthritis	Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Week 26: CDAI	41.2 Percentage of participants
Participants With Rheumatoid Arthritis	Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Week 39: CDAI	37.8 Percentage of participants
Participants With Rheumatoid Arthritis	Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Week 52: CDAI	38.0 Percentage of participants
Participants With Rheumatoid Arthritis	Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Week 65: CDAI	43.7 Percentage of participants
Participants With Rheumatoid Arthritis	Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Week 78: CDAI	40.3 Percentage of participants
Participants With Rheumatoid Arthritis	Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Week 165: CDAI	43.0 Percentage of participants
Participants With Rheumatoid Arthritis	Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Week 13: SDAI	35.2 Percentage of participants
Participants With Rheumatoid Arthritis	Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Week 26: SDAI	41.1 Percentage of participants
Participants With Rheumatoid Arthritis	Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Week 39: SDAI	38.7 Percentage of participants
Participants With Rheumatoid Arthritis	Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Week 52: SDAI	39.2 Percentage of participants
Participants With Rheumatoid Arthritis	Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Week 65: SDAI	45.8 Percentage of participants
Participants With Rheumatoid Arthritis	Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Week 78: SDAI	43.2 Percentage of participants
Participants With Rheumatoid Arthritis	Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Week 103: SDAI	43.5 Percentage of participants
Participants With Rheumatoid Arthritis	Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Week 130: SDAI	44.0 Percentage of participants
Participants With Rheumatoid Arthritis	Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)	Week 165: SDAI	38.0 Percentage of participants

Prospective Evaluation of the Radiographic Efficacy of Enbrel

Conditions

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Other

Participant flow

Recruitment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Change From Baseline in Van Der Heijde Total Modified Total Sharp Score (mTSS) or Adapted mTSS at End of Phase 1 (Week 78): Efficacy Analysis Set (EAS)

Change From Baseline in Van Der Heijde Total Modified Total Sharp Score or Adapted mTSS at End of Phase 1 (Week 78): Completer Analysis Set (CAS)

Change From Baseline in Van Der Heijde Total Modified Total Sharp Score or Adapted mTSS at End of Phase 2 (Week 156): CAS

Change From Baseline in Van Der Heijde Total Modified Total Sharp Score or Adapted mTSS at the End of Phase 2 (Week 156): EAS

Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at End of Phase 1 (Week 78): CAS

Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at End of Phase 1 (Week 78): EAS

Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at End of Phase 2 (Week 156): EAS

Change From Pre-treatment in Normalized Radiographic Progression of mTSS or Adapted mTSS at the End of Phase 2 (Week 156): CAS

Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis

Change From Baseline in Disease Activity Score-28 (DAS-28) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156

Change From Baseline in Hannover Functional Ability Questionnaire (FFbH) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156

Change From Baseline in Inflamed Dactylitic Digits at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis

Change From Baseline in Nail Involvement at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Psoriatic Arthritis

Change From Baseline in Participant Global Assessment (PtGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156

Change From Baseline in Participant Pain Visual Analogue Scale (VAS) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156

Change From Baseline in Physician Global Assessment (PhyGA) of Disease Activity at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156

Change From Baseline in Simple Disease Activity Index (SDAI) at Week 13, 26, 39, 52, 65, 78, 104, 130 and 156 in Participants With Rheumatoid Arthritis

Change From Baseline in Total Erosion Score at End of Phase 1 (Week 78) and Phase 2 (Week 156)

Change From Baseline in Total Joint Space Narrow Score at End of Phase 1 (Week 78) and Phase 2 (Week 156)

Duration of Morning Stiffness in Participants With Temporary Rigidity

Effect on Normalized Radiographic Progression With Respect to Baseline Disease Activity Score-28 (DAS-28)

Effect on Normalized Radiographic Progression With Respect to Baseline Positivity of Anti-citrullinated Protein Antibody (ACPA) - Rheumatoid Factor (RF)

Effect on Normalized Radiographic Progression With Respect to Baseline Usage of Concomitant Medication

Effect on Normalized Radiographic Progression With Respect to Previous Treatment With Biologics

Linear Relationship Between Normalized Radiographic Progression and Disease Duration

Number of Participants Categorized in Different Classes Depending Upon Percentage of Body Surface Area (BSA) Affected by Psoriatic Arthritis

Number of Participants in Each Level of the 5 Dimensions of Health Questionnaire by the EuroQol Group (EQ-5D)

Number of Participants With Use of Glucocorticoids and Disease Modifying Antirheumatic Drugs (DMARDs) Baseline Versus Phase 1 (Week 78) and Baseline Versus Phase 2 (Week 156)

Percentage of Participants With Rheumatoid Arthritis, With Low Disease Activity Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)

Percentage of Participants With Rheumatoid Arthritis, With Remission Based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)

Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Continuation of Treatment With Etanercept

Relationship Between Rheuma Unterstutzungsdienst (RUDI) and Psoriasis Informationsteam (PIT) Participation and Quality of Life Parameters Using Health Questionnaire by the EuroQol Group (EQ-5D)

Number of Participants Who Used Concomitant Medication

Number of Participants With Discontinuation of Etanercept Treatment

Number of Participants With Pregnancy, Puerperium and Perinatal Conditions

Number of Participants With Results of Tolerability Assessment by Physician and Participant

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)

Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity

Number of Participants With Treatment-Emergent Treatment Related Adverse Events